Curriculum vitae - The University of Sydney

Transcription

MARK D. GORRELL BSc PhD
CURRICULUM VITAE
November 2015
21/12/15
Page 1 of 31
CURRICULUM VITAE
Mark Douglas GORRELL BSc(Hons) PhD
Molecular Hepatology Laboratory, Liver Injury and Cancer Program, Centenary Institute
Affiliated with the Royal Prince Alfred Hospital and the University of Sydney Medical School
Telephone
61-2-95656 152
Facsimile
61-2-95656 101
E-mail
[email protected]
Address
Centenary Institute, Locked Bag No.6, Newtown, NSW 2042. Australia
Location
Johns Hopkins Drive, Camperdown, NSW, 2050. Australia
URL
http://sydney.edu.au/medicine/people/academics/profiles/mark.gorrell.php
Born
1956 at Camden, New South Wales, Australia
Nationality
Australian
QUALIFICATIONS
Bachelor of Science [Honours], Australian National University conferred 1978.
Doctor of Philosophy, Australian National University conferred 1982.
PRESENT CLASSIFICATION
Associate Professor of the University of Sydney Medical School.
University of Sydney employee.
PRESENT APPOINTMENTS (Voluntary)
• Molecular Hepatology Laboratory Head in the Liver Injury and Cancer Program of Centenary
Institute.
• Associate Faculty member in the Centenary Institute.
• Sub-Dean (Postgraduate Research) for Centenary Institute, Sydney Medical School.
• Chair, Centenary Institute Equipment Grants Committee.
• Centenary Institute Commercialisation Committee Member.
• Editorial Board, Scientific Reports.
• Editorial Board, World Journal of Gastroenterology.
• Immediate Past Treasurer, International Proteolysis Society.
• Gastroenterological Society of Australia Research Committee member.
• Grant Review Panel member, National Health and Medical Research Council of Australia.
• Rebecca L Cooper Medical Research Foundation Scientific Advisory Committee member.
RESEARCH INTERESTS
Understanding the functions of the prolyl oligopeptidase gene and enzyme family, and roles in
diabetes and the molecular pathogenesis of chronic liver disease.
APPOINTMENT HISTORY
Feb 2007 –
Associate Professor
AW Morrow Gastroenterology and Liver Centre
Discipline of Medicine
Central Clinical School
Sydney Medical School
The University of Sydney
Nov 2007 –
Associate Faculty and Molecular Hepatology Laboratory Head,
Liver Injury and Cancer Program
Centenary Institute, Sydney Medical School, University of Sydney
Appointment history in the University of Sydney 1995 to 2007
June 2005 – Feb 2007 Principal Research Fellow
Aug1999 to Jun 2005
Senior Research Fellow
21/12/15
Page 2 of 31
Jun 1995 to Aug 1999
Research Fellow
Discipline of Medicine
Central Clinical School
Faculty of Medicine
The University of Sydney
Appointment history in the Royal Prince Alfred Hospital 1994 to 2007
April 2004 – Feb 2007
Principal Hospital Scientist
Nov 2002 to April 2004 Senior Hospital Scientist
Jun 1995 to Nov 2002
Jan 1994 to Jun 1995
Senior Research Officer
Royal Prince Alfred Hospital
Sep 1991 to Dec 1993
Senior Research Associate
Neurovirology Laboratories
The Johns Hopkins University School of Medicine
Baltimore, MD, USA
Nov 1989 to Sep 1991
Retrovirus Biology Laboratory
Division of Comparative Medicine
The Johns Hopkins University School of Medicine
Baltimore, MD, USA
Jul 1988 to Nov 1989
Senior Hospital Scientist
A.W. Morrow Gastroenterology and Liver Centre
Royal Prince Alfred Hospital, Camperdown, Australia
Mar 1984 to Jun 1988
Research Fellow
Centre for Animal Biotechnology
School of Veterinary Science
The University of Melbourne at Parkville
Feb 1982 to Feb 1984
Senior Scientist (project leader)
Australian Monoclonal Development Pty Ltd. [a small biotech]
65 Dickson Ave, Artarmon, NSW, Australia
EDUCATION
1978 to 1981
1977
1974 to 1976
Doctor of Philosophy, conferred April 1982.
Department of Zoology, Australian National University.
PhD Thesis: "Monoclonal Antibodies to Fasciola hepatica".
Supervisor: Dr M.J. Howell
Honours Thesis: "Antigenic Analysis of Fasciola hepatica".
Bachelor of Science, Australian National University.
Majors: Parasitology, Vertebrate Zoology, Biochemistry.
The three major impacts of my research:
1. My discovery, with Dr Abbott, of two enzymes, DPP8 and DPP9, enabled the Merck Corporation to
counter screen on these enzymes when developing the first compound, sitagliptin, which selectively
inhibits DPP4 but not DPP8 or DPP9. This selective inhibitor is the most successful type 2 diabetes
st
therapy of the 21 century. Many other pharmaceutical companies now market similarly selective, safe
and effective DPP4 inhibitors. Some such companies licensed DPP8 and contracted me as a consultant
or to evaluate DPP4 selectivity. DPP4 inhibitors obtained FDA approval in the USA in 2006 and entered
the Australian Public Benefit Scheme in 2008. My recent discovery that DPP9 enzyme deficiency is lethal
in young mice [Gall et al 2013] confirms that DPP4 selectivity is essential.
2. Our pioneering establishment in Australia of DNA microarray analysis of gene expression in diseased
liver led to the novel identification of many disease-associated genes. These discoveries, such as roles
for WNT, DDR1, Hedgehog, CD147 and Th1 cells, have been built upon by us and many labs to better
21/12/15
Page 3 of 31
understand chronic liver disease. These projects were funded by the peak bodies of both Australia and
USA, NHMRC (358398; McCaughan, Gorrell) and NIH (RFA/DK/98.017; Farrell, McCaughan, George).
3. Both DPIV and the DPIV-related enzyme fibroblast activation protein [FAP] are made by tumour
stromal fibroblasts. We discovered that FAP is also readily detected in diseased but not healthy liver and
that its abundance is proportional to scarring severity. FAP has since been found in other fibrotic
diseases. We have shown that FAP influences cell adhesion, migration and death in vitro. We found that
FAP is probably a useful diagnostic for liver fibrosis. Many labs worldwide are now examining potential
FAP-targeted disease therapies.
RESEARCH GOALS
My primary long-term goal is to progress towards an understanding of disease pathogenesis and to
learn to harness this knowledge to improve disease outcomes. To this end I have been studying
leukocyte phenotypes and the kinetics of local immune responses, comparing effective and ineffective
immune responses, biochemical and serological analyses of the glycoproteins of pathogens and
mammals. While advancing toward this goal I have accumulated extensive experience in cell biology,
immunology and protein biochemistry. My focus has been the pathogenesis of liver diseases, tumours,
parasites, bacteria and viruses, in particular immune responses.
I realigned my research into medical research during the 1990s by retraining. I am now primarily
interested in the pathogenesis of cirrhosis and the roles of a specific class of peptidases, the prolyl
oligopeptidases, which includes dipeptidyl peptidase (DPP) 4, DPP8, DPP9 and FAP (fibroblast activation
protein).
PRODUCTIVITY SUMMARY 1999Income average per scientist per year 2009-2015: $90,000.
Table: Research income ($ thousands)
Year
Program
Project Scholar- Travel
Applied
grant*
grants ships
awards research
**
1999
128
2000
50
2001
191
17
1
2002
70
56
3
2003
206
56
4
2004
277
72
4
46
2005
90
398
72
6
66
2006
90
181
68
4
52
2007
90
196
58
9
12
2008
90
261
40
1
2009
90
216
26
4
2010
140
274
24
7
2011
144
154
34
10
2012
146
288
96
13
2013
119
183
69
12
2014
124
91
84
9
2015
0
48
31
12
2016
0
485
20
Totals
1,123
3,697
670
107
176
Equipment
***
40
9
17
63
62
397
105
0
242
345
20
45
19
89
22
22
1,549
Annual
Totals
168
50
218
146
329
461
1,029
500
365
634
681
465
387
562
472
308
113
505
7,427
Cummulative
Totals
168
218
436
582
911
1,372
2,401
2,901
3,266
3,900
4,581
5,046
5,433
5,995
6,497
6,827
6,922
7,427
* Amounts are allocations to my group from the NHMRC Program Grants 358398 and 571408.
**Research funds from companies.
*** Equipment grants >$30,000 were generally awarded to consortia of many academics.
Supervision of PhD Completions:
15
Supervision of Masters of Medicine / MPhil Completions:
two
Scholarships awarded to students: 13 (6 NHMRC, 7 APA, 1 UPA, 2 SydUni)
Current supervision of postgraduate research students: two primary, 1 secondary
Current supervision of employees:
two
Current Collaborations: Centenary Inst, Univ Sydney, interstate, international
21/12/15
Page 4 of 31
PUBLICATIONS
Parameter
Total
mean per
year
4.5
135
3.9
mean per
paper
All publications 26 years
119
*Citations
3506
49
Peer-reviewed publications
103
Book chapters / reviews
33
Editorials / commentaries
7
Patents
5
Papers having an IF
78
2.8
Impact Factor [IF]
308
12
4.3
Papers in journals of IF 9+
13
0.5
0.18
Papers in journals of IF 3 to 9
29
1.3
0.47
Citations per IF > two years
567
24
7.7
post-publication
* Data collected November 2013. Impact Factors [IF] are 2013 data.
PUBLICATIONS since 1999
Parameter
Total
Publications in the last 15 years
Papers having an Impact Factor
Impact Factor
*Citations occurring since 1999
82
52
263
2881
mean per
year
6.3
3.5
17.5
179
Year 2013
2014
7
375
7
3
0
0
5
25.6
1
4
5
426
5
2
5
3
mean per
paper
65
52
2015 Hirsch’s h-Index = 38.
i10 index = 80
Last 5 years 2010-2015 h-Index = 28, i10 index = 55.
Citations; 4,845
Citations in last 5 years [2010-2015]; >2,350
2014 h = 36, i=74; 2013 h = 31; 2012 h = 26; 2011 h = 26; 2010 h = 24; 2009 h = 23; 2008 h = 22;
2007 h = 22.
The six most-cited papers: 350, of Oravecz 1997; 310 of Cox 2003; 263 of Gorrell 2001; 216 of Abbott
2000; 223, of Gorrell 2005; 190, of Levy 1999.
PERSONAL INTERESTS
Ancient history, tennis, gardening, pilates, travel.
GRANTS AND AWARDS
1978-81 Australian Wool Corporation Postgraduate Scholarship.
1986-88 Australian Wool Corporation project grant, MD Rickard, MR Brandon & MD Gorrell "Cellular
immune responses to cysticercosis". $150,000 over 3 years.
1994-96 NHMRC project grant, GW McCaughan & MD Gorrell: “Structure and Function of Dipeptidyl
Peptidase IV (CD26)”. $211,000 over 3 years.
1995 NHMRC equipment grant, GA Bishop, MD Gorrell & GW McCaughan: Ultra-low temperature
freezer. $13,900.
1996 RK Baird Travel Award $700. MD Gorrell
1996 Human Leucocyte Differentiation Antigen Congress Travel Bursary $1,600. MD Gorrell
1997-99 NHMRC project grant, GW McCaughan & MD Gorrell: “Molecular analysis of the
multifunctional glycoprotein dipeptidylpeptidase IV“. $234,000 over 3 years.
1997 RIEF (Australian Research Council). Member of Consortium led by A/Prof. R. I. Christopherson,
Univ. Sydney. Recombinant Protein Facility. $185,000.
1998 Wellcome Trust. Member of Consortium led by A/Prof. R. Christopherson, Univ. Sydney.
Identification and characterisation of purified recombinant proteins by high pressure liquid
chromatography-mass spectrometry. $517,164.
21/12/15
Page 5 of 31
1998 RIEF (Australian Research Council). Member of Consortium led by Prof. R. Raison, UTS. A facility
for the analysis of biomolecular interactions. $254,160.
1998 The Clive and Vera Ramaciotti Foundation. Member of Centenary Institute consortium. Automated
cell counter. $20,000.
1999 Ramaciotti Foundation. Member of Centenary Institute consortium. Multi-label plate reader.
$40,000.
1999 Anonymous Philanthropic grant. “Inflammation of the gut and liver”. MD Gorrell $150,780 over 3
years.
2001 Australian Brewers' Foundation project grant; “Microarray analysis of intrahepatic gene expression
in alcoholic liver disease”. P. Haber, M. Gorrell, G. McCaughan, R. Batey $40,688.
2001-03 NHMRC project grant 142606; “The Role of Fibroblast activation protein in Chronic Liver
Injury.” GW McCaughan, MD Gorrell $255,000 over 2001-2003.
2001 NHMRC equipment grant; “Incubator for insect cell culture.” MD Gorrell, J Rasko, C Demangel,
GW McCaughan, $9,455.
2001 University of Sydney Sesqui grant; “Microarray analysis of intrahepatic gene expression in alcoholic
liver disease”. P. Haber, M. Gorrell, G. McCaughan $30,000.
2002 Rebecca L. Cooper Foundation: “Functional Genomics in Liver and Lung Diseases.” GW
McCaughan, MD Gorrell, B. Saunders. $9,200.
2002 NHMRC equipment grant; “Nucleic Acid Extraction Facility.” MD Gorrell, GA Bishop, GM Halliday,
WJ Britton $7,510.
2003 Rebecca L. Cooper Foundation: “Nucleic Acid Extraction Facility.” GW McCaughan, MD Gorrell,
GA Bishop, GM Halliday $16,000.
2003-05 NHMRC / Department of Veterans Affairs project grant 253820; “Microarray analysis of
intrahepatic gene expression in alcoholic liver disease”. P. Haber, M. Gorrell, G. McCaughan
$255,000 over 2003-2005.
2003 Ernest Heine Foundation. Equipment grant; Cryostat for the study of human liver diseases. G.
McCaughan, M. Gorrell, A. Basten. $46,795.
2004 Rebecca L. Cooper Foundation: “Localising gene expression.” GW McCaughan, MD Gorrell, B.
Saunders. $16,000.
2004 NHRMC Equipment grant. Recombinant Protein Facility. Mark D Gorrell, Alexandra F Sharland, Dr
Paul S Haber, Dr G Alex Bishop, Prof Geoffrey W McCaughan. $16,268.
2004 NHMRC project grant 293803; “Roles of the dipeptidyl peptidase IV gene family in Human Liver
Disease.” MD Gorrell, GW McCaughan, $79,750.
2004 Clive and Vera Ramaciotti Foundation. High speed centrifuge for DNA preparation. AF Sharland,
RD Allen, GA Bishop, S Chadban, JM Eris, H Wu, C Wang, GW McCaughan, MD Gorrell, A
Abendroth $30,000
2004 Applied research grants from Pharma. Compound selectivity for DPIV. M. Gorrell. $46,000
2004-06 Anonymous Philanthropic grant. “What are the biological or disease outcomes of lacking DP8 or
DP9”. MD Gorrell $174,402 over 3 years [58.14K pa].
2005-09 NHMRC Program grant 358398. Molecular and cellular pathogenesis of human liver disease.
G. Farrell, G. McCaughan, J. George (CIs) and Principal Investigators Gorrell, Bertolino, Teoh,
Shackel, Bowen, Leclerq. $4.6 million over 5 years. [$926,000 in 2005, $938,000 in 2006 etc]
2005 University of Sydney R & D grant. Human biology of dipeptidyl peptidases. GW McCaughan, M
Gorrell. $49,006
2005 Ferring Research Ltd, Southhampton, UK. Project grant. Liver fibrosis, M. Gorrell. $79,000
2005 Rebecca L. Cooper Foundation. HPLC protein separation. W. Britton, G. W. McCaughan, M.
Gorrell, J. Allen. $16,000
2005 University of Sydney Equipment grant. High performance liquid chromatography protein separation.
Consortium led by Prof W. Britton. $45,000
2005 University of Sydney Equipment grant. FACS Aria. Consortium led by A/Prof Nick King. $248,000.
2005 NHMRC Equipment grant. Cooled gradient palm cycler and rotor-shake genie. GA Bishop, AF
Sharland, S Chadban, RDM Allen, MD Gorrell $10,750.
2005 Perpetual Trustees Equipment grant. HPLC protein separation. W. Britton, G. W. McCaughan, M.
Gorrell, J. Allen. $17,500
2005 Cancer Institute NSW Research Infrastructure Grant. Gel imaging facility. John Allen, Mark Gorrell,
Rosetta Martiniello-Wilks, Stephen Clarke, Jonathon Arnold. $60,000
2005-07 Interactions between porcine ligands and the human lymphocyte activating receptor NKG2D AF
Sharland, MD Gorrell, M Sandrin, D Christiansen. ID: 619321310. Roche Organ Transplantation
Research Foundation. $220,000 over 3 years. [$71,000 in 2007]
21/12/15
Page 6 of 31
2006 Applied research grants from Pharma including Boehringer Ingelheim, Glenmark and Servier.
Compound selectivity for DPIV. M. Gorrell. $52,000
2006 NHMRC Equipment grant. G. W. McCaughan, Mark Gorrell, Alexandra Sharland, Paul S. Haber,
Bret W. Church, Patrick Bertolino Refrigerated Incubator and Analytical Apparatus $29,918
2006 Probiomics Ltd. Probiotics and immune responses. Mark Gorrell, $10,000.
2006 Univ Sydney Equipment grant. W Britton, B Fazekas, GW McCaughan, M Gorrell, J Rasko, J
Triccas, A Abendroth, B Saunders. Assessing cell proliferation. $50,171
2006 Clive and Vera Ramaciotti Foundation. W Britton, B Fazekas, GW McCaughan, M Gorrell, J
Rasko, J Triccas, B Saunders. Assessing cell proliferation. $25,000
2007-09 Anonymous Philanthropic grant. “Prolyl oligopeptidases in the pathobiology of chronic liver
injury”. MD Gorrell $195,021 over 3 years [$65,007 pa].
2008 DPIV expression and nanospheres. Ceramisphere Ltd. M. Gorrell. $10,000
2008 ARC LIEF LE0883068 awarded to University of Sydney consortium led by Bret Hambly: BD
Hambly, S Bao; GA Bishop; J Black; IL Campbell; Q Dong; MD Gorrell; GE Grau; NH Hunt; NJ
King; R Markham; DJ Marsh; KL McDonald; SV McLennan; KJ Rodgers; D Seth. Dako ACIS III
Cellular Image Acquisition and Analysis System. $150,000
2008-2010 NHMRC project grant 512282; “Therapeutic potential of the dipeptidyl peptidase IV gene
family.” MD Gorrell, $458,750. [153 pa]
2008 NHMRC Equipment grant. Mark Gorrell, Christopher Semsarian, Pu Xia, John Allen, Mika
Jormakka, Geoffrey W. McCaughan, John Rasko, Mathew Vadas, Fiona Warner, Devanshi Seth,
Tatiana Tsoutsman, Jeff Holst, Silvia Ling. Advanced multiparameter quantitation station. $37,127.
2008 NHMRC Equipment grant awarded to University of Sydney consortium led by Prof Nick King: NJ
King, BD Hambly, S Bao; GA Bishop; J Black; IL Campbell; Q Dong; MD Gorrell; GE Grau; NH
Hunt; R Markham; DJ Marsh; KL McDonald; SV McLennan; KJ Rodgers; D Seth. Dako ACIS III
Cellular Image Acquisition and Analysis System. $24,375
2008 Perpetual Trustees Clive and Vera Ramaciotti Equipment grant. Fluorescence polarization reader
with high performance luminescence. CI: Mathew Vadas. Co-investigators: Mark Gorrell,
Christopher Semsarian, Pu Xia, John Allen, Mika Jormakka, Geoffrey McCaughan, John Rasko,
Warwick Britton, Barbara Fazekas, Wolfgang Weninger, Jennifer Gamble, Nicholas West, Fiona
Warner, Chris Jolly, Devanshi Seth, Charles Bailey, Jeff Holst. $30,000
2009 Rebecca L Cooper Foundation Equipment grant. Fluorescence polarization reader with high
performance luminescence. M Gorrell, P Xia, GW McCaughan, J Rasko, M Vadas, B Fazekas, W
Weninger, J Gamble, M Jormakka, C Jolly, F Warner, D Seth, C Bailey, J Holst. $20,000
2009 NHMRC Equipment grant awarded to University of Sydney consortium led by Prof Nick King: Flow
Cytometry, $200,000
2009 NHMRC Equipment grant awarded to Centenary Institute consortium led by Prof Wolfgang
Weininger: Inverted Multiphoton, $75,000
2010-12 Anonymous Philanthropic grant. “Dipeptidyl peptidases in biology”. MD Gorrell $220,521 over 3
years [$73,507 pa].
2009 Perpetual Trustees Clive and Vera Ramaciotti Equipment grant. “Live cell imaging”. CI: Mathew
Vadas. Centenary Institute Consortium led by N Haass & N Shackel. $50,000
2010 Rebecca L Cooper Medical Research Foundation Ltd Equipment grant. “Human protein production
at 27 degrees”. M D Gorrell, WB Church, AF Sharland $20,000
2010-2012 NHMRC Project grant 632822. “Diabetes exacerbates non-alcoholic steato-hepatitis (NASH)”.
A/Pr S Twigg A/Pr S McLennan A/Pr M Gorrell. $545,500 [$136,375 to MDG].
2010-2014 NHMRC Program Grant 571408 awarded to M Vadas, GW McCaughan, J Gamble, P
Bertolino, P Xia provides some funds for my research.
2011 NHMRC Equipment grant awarded to a University-wide consortium led by Dr Mika Jormakka.
“Automated storage, retrieval, and UV imaging system of protein crystallization”, $45,000. CIs Mika
Jormakka, Jennifer Gamble, Chris Semsarian, John Rasko, Mathew Vadas, Pu Xia, Mark D
Gorrell, Ronald Clarke, Megan Maher, Jeff Holst, W. Bret Church. RIMS 2011-00151
2011 University of Sydney bridging grant. “Therapeutic uses of DPP-IV and related proteins”. MD Gorrell
$50,000.
2012 Diabetes Australia Research Trust General Grant. “Targeting proteases for a novel therapy for type
2 diabetes and liver complications”. MD Gorrell $59,814.
2012-14 Anonymous Philanthropic grant. “DPP-IV and FAP in Chronic Liver Disease”. MD Gorrell
$272,160 over 3 years [$90,720 pa].
2012-2013 Group of Eight Australia - Germany Joint Research Co-operation Scheme funded by DAAD
[Deutscher Akademischer Austauschdienst]. “A novel approach to understanding tumour
development”. O. Schilling 18,000Euro, MD Gorrell $18,000 .
21/12/15
Page 7 of 31
2012-2013 Australian Centre for HIV and Hepatitis Virology Research (ACH2) MD Gorrell, A Zekry, GW
McCaughan, A Lloyd. Novel outcome predictors in HCV post-liver transplant. $193,000.
2012 Perpetual Trustees Equipment grant. Automated electrophoresis. Consortium led by C. Jolly
$30,000.
2013 University of Sydney Equipment Grant Scheme. F. Braet, A. Weiss, N. King, C. dos Remedios, D.
Traini, M.B. Graeber, C. Murphy, G. Grau, L. Soon, T.P. Newsome, C. Goldsbury, M. Lovelace,
M.D. Gorrell, C. Pollock. Wide field super-resolution microscopy with ground state depletion —
Exploring nanoscopic life in chronic diseases. USYD 2012-02785. $89,262.
2014 Rebecca L Cooper Medical Research Foundation Ltd Equipment grant. “Protease therapies for
diabetes-associated liver disease”. M D Gorrell, F M Keane, A Cook, N A Shackel, D Seth, J
Chen, C Jolly, N Hare, G W McCaughan. Grant 10142. $22,000
2014-16 Anonymous Philanthropic grant. “DPP-IV and FAP in Cancer”. MD Gorrell $312,000 over 3
years [$104,000 pa].
2015 Rebecca L Cooper Medical Research Foundation Ltd Equipment grant G178196. “Novel therapy
approaches for diabetes and its liver and heart complications”. M D Gorrell [supported by F M
Keane, T Tu, NA Shackel, D Bowen, P Bertolino, D Seth, JB Chen, A Cook, R Liu, XJ Zheng, J
Gamble, G W McCaughan]. $22,000
2015 Centenary Institute Near-miss scheme. M D Gorrell. $48,000.
2016 Diabetes Australia Research Trust General Grant. “Preclinical evaluation of a new therapy for type 2
diabetes.” Mark D Gorrell $60,000. Offer withdrawn due to CIA holding an NHMRC grant.
2016-20 NHMRC Project Grant 10105238. “DPP4 family proteases as drivers of chronic liver injury”. A/Pr
MD Gorrell, Prof GW McCaughan, Prof S Twigg, Prof WW Bachovchin. 2016 $215,650, 2017
$200,650. 2018 $205,650, 2019 $40,496. 2020 $67,594. Total $730,040.
2016-18 NHMRC Project Grant 1099375. “Diabetes drug for ovarian cancer”. A/Pr Magdelina Plebanski,
Dr Andrew N Stephens, Prof Martin Oehler, A/Pr MD Gorrell. $711,966, with $10,000 p.a. to
Gorrell lab.
2016-17 NHMRC Development Grant 1113842. “A novel liver cancer therapy targeting tumour stroma”.
A/Pr MD Gorrell, Prof GW McCaughan. 2016 $187,252, 2017 $200,650 Total $387,902.
Licensing income to University from developed IP: Non-exclusive license fees paid to the University for
DP8 and DP9 patents and expenses are managed by the University Business Office (Sydnovate).
The primary use of the patents is to measure the selectivity of Dipeptidyl Peptidase IV inhibitors
being used for type 2 diabetes therapy.
Regarding significance see UniNews item, “Sydney’s key role in diabetes success” by E. Heath. March
21, 2008.
Maintaining this IP including responses to patent office reports, associated commercial projects
and liason with Sydnovate occupied my significant attention 1998-2015.
Postgraduate student scholarships awarded to supervised students.
1996- 00 NHMRC scholarship; PhD: Miriam T. Levy. Hepatic stellate cells in human cirrhosis.
1997- 00 NHMRC scholarship; M. Med.: Colin Ong. Expression of DPPIV, FAP and CD13 in human skin
cancer.
1998- 01 NHMRC scholarship; PhD: Nicholas A. Shackel. Differential gene expression in human
cirrhosis. Primary supervisor Prof G. McCaughan.
2001- 04 APA scholarship; PhD: Xiao Xuan {Jane} Huang. Pathogenesis of human cirrhosis.
2002- 05 UPA scholarship; PhD: Joohong Park. Expression, purification and characterisation of dipeptidyl
peptidase 8 and DPIV.
2002- 06 NHMRC scholarship #219707; PhD: Denise MT. Yu. Functional studies of Dipeptidyl Peptidase
8 (DP8) and DP9.
2003- 07 NHMRC scholarship; PhD: Xin {Maggie} Wang. Fibroblast activation protein in cell biology and
liver fibrosis.
2004- 07 NHMRC scholarship #307818; PhD: Katerina Ajami. Dipeptidyl Peptidase 9 expression and
action.
2004- 07 APA scholarship; PhD: Peter Tran. Porcine NKG2D ligands. Primary supervisor Dr A.F.
Sharland.
2007-11 APA scholarship; PhD: Naveed Ahmed Nadvi. Epitope tags in structural biology. Primary
supervisor W. Bret Church of Pharmacy.
2007-10 APA scholarship; PhD: Tsun-Wen {Sheena} Yao. Fibroblast activation protein and DPP9.
2009-13 International scholarship; PhD: Yiqian Chen. Dipeptidyl Peptidase gene expression.
21/12/15
Page 8 of 31
2011-14 APA scholarship; PhD: Elizabeth J. Hamson. Endopeptidase substrates.
2012
APA scholarship; PhD: Yuan Zhou Zheng. Dipeptidyl Peptidases in chronic liver injury.
2012-15 APA scholarship; PhD: Hui [Emma] Zhang. Functions and biochemistry of Dipeptidyl Peptidase
9.
2012-15 Sydney Medical School scholarship; PhD: Margaret G. Gall. In vivo function of Dipeptidyl
Peptidase 9.
2015Newington Alumni scholarship; PhD: James Henderson. Liver Cancer.
2015APA scholarship; PhD: Kaitlyn A Preece. The intestinal microbiome, diet and proteases.
TEACHING
THESIS Examinations / student guidance
✹
✹
✹
✹
✹
✹
✹
✹
✹
✹
✹
✹
University of Melbourne. Three PhD theses 1996-2005.
University of South Australia and Flinders. MSc thesis 1999. Honours 2004. MSc thesis 2007.
University of Sydney. 1 Masters of Medicine, 10 honours theses, 1998Monash University PhD thesis 2005, 2010, 2011, 2015.
University of Adelaide. PhD thesis 2010.
Australian National University. PhD thesis 2012.
University of Sydney. 4 PhD theses 2011, 2014, 2015.
University of Queensland. PhD thesis: 2015.
University of Sydney Medicine Central Clinical School Postgraduate Student Review Committee
membership 2003-.
University of Sydney Medicine Central Clinical School Postgraduate Student Co-ordinator [acting]
Oct 2006.
Centenary Institute Postgraduate Student Midpoint Review Committees 2002 onwards. [chair seven
times].
Centenary Institute Higher Degree Committee since 2006.
Teaching postgraduate students of the University of Sydney
Thirteen completions, ten as primary supervisor.
1994-98 PhD: Catherine A. Abbott (BSc). Molecular studies of human glycoprotein DPIV/CD26. Primary
supervisor Prof GW McCaughan.
1996- 00 PhD: Miriam T. Levy (MB BS, FRACP). Hepatic stellate cells in human cirrhosis.
1997- 00 M. Med.: Colin Ong (MB BS). Expression of DPIV, FAP and CD13 in human skin cancer.
1998- 01 PhD: Nicholas A. Shackel (MB BS, FRACP). Differential gene expression in human cirrhosis.
Primary supervisor Prof G.W. McCaughan.
2001-04 PhD: Xiao Xuan {Jane} Huang (MD, M. Med.). Pathogenesis of human cirrhosis.
2002-05 PhD: Joohong Park (BSc, M Sc). Expression, purification and characterisation of dipeptidyl
peptidase 8 and DPIV.
2002-06 PhD: Denise Ming Tse Yu (B Med Sci (Hons)). Functional studies of Dipeptidyl Peptidase 8
(DP8) and DP9.
2003-08 PhD: Sunmi Song (BSc (Hons). Molecular pathogenesis of fibrosis.
2003-07 PhD: Xin {Maggie} Wang (BSc, MMed). Fibroblast activation protein in cell biology and liver
fibrosis.
2004-08 PhD: Katerina Ajami. (B Med Sci (Hons)). Functional characterisation of DP8 and DP9.
2004-10 PhD: Peter Tran (B Med Sci (Hons)). Porcine NKG2D ligands. Primary supervisor Dr AF
Sharland. Withdrew from degree.
2005-11 PhD: Lisa Wing-Yee Lo (B Med Sci (Hons)). Roles of profibrotic cytokines in liver fibrosis in
diabetes. Primary supervisor Pr S. Twigg.
2007-11 PhD: Naveed A. Nadvi (BSc (Hons). Epitope tags in structural biology. Primary supervisor W.
Bret Church of Pharmacy. Submitted 2012. Awarded Dec 2012.
2007-10 PhD: Tsun-Wen Yao B. Biotech, M. App. Biotech. FAP and DPP9. Submitted 2.9.10. Awarded
2011. Graduated Dec 2011.
2009-10 M Med: Sumaiya Chowdhury BSc (Hons). DPIV and FAP in metabolism. Awarded 30.11.10.
Graduated Apr 2011. Cosupervisor Dr D. Yu.
2009-13 PhD: Yiqian Chen BSc MSc. Dipeptidyl Peptidase gene expression and substrates.
Cosupervisor Dr D. Yu.
21/12/15
Page 9 of 31
2011-15 PhD: Elizabeth J. Hamson B. Med. Sci. (Hons): Proteinase degradomes. Cosupervisor Dr F.
Keane.
2012
PhD: Yuan Zhou Zheng BSc (Hons) (Univ Sydney). Withdrew from degree. Cosupervisor Pr S.
Twigg.
2012-15 PhD: Hui [Emma] Zhang B Pharm (China) M Appl Sci (Univ Sydney). Functions and
biochemistry of Dipeptidyl Peptidase 9. Cosupervisor Dr F. Keane.
2012PhD: Margaret G. Gall BSc MSc (Univ Sydney). In vivo function of Dipeptidyl Peptidase 9.
Cosupervisor Dr F. Keane.
2012-15 PhD: Kathryn Williams MBBS (Univ Sydney). Diabetes complications. Primary supervisor Prof S
Twigg.
2014PhD: James M. Henderson BSc Hons (Univ Sydney). Dipeptidyl Peptidases in liver cancer.
Cosupervisors Dr F. Keane, Prof GW McCaughan.
Teaching Honours research students of the University of Sydney
Fourteen honours thesis completions, six as primary supervisor.
1997
B. Med. Sci. Honours Class 1: Loubnah Zaydan-Slaitini. Effects of soluble CD26 on T cell
proliferation.
1998
B. Sci. Molec. Biol. Honours Class 1: Denise Yu. Cloning a novel prolyl oligopeptidase. Primary
supervisor Dr C Abbott.
1999
B. Med. Sci. Honours Class 1+ University medal: Vanessa Gysbers. The adenosine deaminase
binding activity of CD26.
1999
B. Med. Sci. Honours Class 1: Katerina Ajami. Cloning novel prolyl oligopeptidases. Primary
supervisor Dr C. Abbott.
2000
B. Med. Sci. Honours Class 1: Mina Obradovic. Characterisation of a novel dipeptidyl peptidase,
DP8. Primary supervisor Dr C. Abbott.
2002
B. Med. Sci. Honours Class 1: Yvonne Brennan. Pathogenesis of alcoholic liver disease.
Primary supervisor Dr D. Seth.
2006
B. Med. Sci. Honours Class 1+ University medal: Sarah Richardson. Role of EMMPRIN in liver
disease. Primary supervisor Dr N. Shackel.
2006
B. Med. Sci. Honours Class 2: Jamai Rahim. Osteopontin in alcoholic liver disease. Primary
supervisor Dr D. Seth.
2006
B. Med. Sci. Honours Class 1: Betty Chow. ACE2 biochemistry in liver disease. Primary
supervisor Dr F. Warner.
2006
B. Sci. Honours Class 1: Naveed Nadvi. KAT-1 biochemistry. Primary supervisor W. B. Church
of Pharmacy.
2008
B. Med. Sci. Honours Class 2: Sumaiya Chowdhury. DPIV family expression in the immune
system. Cosupervisors Dr D. Yu, Dr S. Song.
2010
B. Med. Sci. Honours Class 1: Elizabeth Hamson. Fibroblast activation protein. Cosupervisor Dr
F. Keane.
2010
B. Sci. Honours Class 1: Alastair Duly. DPIV gene family polymorphisms. Cosupervisors Dr D.
Yu, Dr R. Bagnall.
2011
B. Pharm. Honours Class 1: Zainab Reslan. Structure based drug design. Primary supervisor Dr
W B Church.
2012
B. Pharm. Honours Class 1: Amanda Elaro. Prolyl endopeptidase. Primary supervisor Dr W B
Church.
2012-14 GMP / MBBS Honours. Pok Fai Wong B.Med.Sci. Substrates of FAP and DPP-IV. Cosupervisor
Dr FM Keane.
2015
B. Med. Sci. Honours. Jonathan Vincent. Immune roles of FAP and DPP-IV. Cosupervisor Dr
Ben Roediger.
Teaching Postgraduate students:
Supervision of GRE 2014: The USA postgraduate research student entrance exam .
Teaching Postgraduate students: supervision of short Masters research projects.
2002-03 Sarah Boustany. Primary supervisor Dr G. Cox.
Mr Min Hooi Tai 2005. Associate supervisor Ms Denise Yu.
Ms Tsun-Wen Yao 2006. Associate supervisor Ms Sunmi Song.
Ms Jené Roestorf 2007. Associate supervisor Dr Denise Yu.
21/12/15
Page 10 of 31
Mrs Margaret G. Gall 2008. Associate supervisor Dr Denise Yu.
Ms Priscilla Tourany 2009. Associate supervisor Dr Denise Yu.
Teaching Undergraduate students: supervision of research experience
Nearly all were students of the University of Sydney
Mr Lim, Mr Yeo were enrolled in the University of Sydney Molecular Biotechnology Program.
Ms Reikhoff was here as an essential course requirement for her medical degree (University of
Gröningen, Holland).
Stephanie Seelk was a student in Diploma in Biochemistry and Molecular Biology, Friedrich-SchillerUniversity, Jena, Germany.
Marja Kornhuber was a student in Biochemistry, Free-University, Berlin, Germany.
Mr N. Narayan 1990
Mr C. Chin 1993
Ms Denise M.T. Yu 1996
Ms Belinda Creighton 1997
Ms Jennifer Ho 1998
Ms Hannah J.D. North 1999,
Mr Kenny Wan 2000,
Ms Francine Portelli 2000/1,
Ms Konsita Kuswara 2001.
Ms Souraya Hijazi 2001/02,
Ms Lisa Lim 2001/02.
Ms Netke Reikhoff 2002.
Ms Valerie Tan 2002/03.
Ms Wimonrat Hoasawadut 2003.
Mr Ricky Lim 2003.
Mr Jiun Tzen Yeo 2006.
Libby Hamson 2009.
Kaitlyn Preece 2010-12.
Stephanie Seelk 2011.
Marja Kornhuber 2012.
Lectures for postgraduate teaching courses
Immune responses to viruses in the central nervous system. Postgraduate Course in Immunology.
Centenary Institute of Cancer Medicine and Cell Biology. June 1996.
Manufacturing recombinant glycoproteins in mammalian cell culture. Postgraduate Course in
Molecular Biology, University of Sydney Faculty of Medicine. August, 1997.
Liver Inflammation. Postgraduate Course in Immunology. Centenary Institute of Cancer Medicine and
Cell Biology. June 1998 and 1999.
Pathogenesis of Chronic Liver Diseases. Postgraduate Course. Centenary Institute of Cancer
Medicine and Cell Biology. Sept 2002.
Biology of Prolyl Oligopeptidases. Pharmacy. March 2007.
Supervision of Research Assistants (external funding)
1999-2004 Katerina Ajami, B Med Sci (Hons) (Univ Sydney)
2001-2004 Xin (Maggie) Wang, BSc (Peking), MSc (Univ Sydney)
2005-2008 Kathryn A. Evans, B Med Sci (Hons) (James Cook University)
2005-2010 Brenna Osborne, BSc (Hons) (Univ Sydney)
2008-2012 Margaret G. Gall BSc MSc (Univ Sydney)
2009-2013 Ana Júlia Vieira de Ribeiro BSc MSc (Universidade Federal do Rio de Janeiro)
2010Sumaiya Chowdhury BSc (Hons) M Med (Univ Sydney)
Supervision of postdoctoral research fellows (external funding)
1999-2001 Catherine A Abbott, BSc PhD (Univ Sydney). Primary supervisor Prof GW McCaughan.
2001-2004 Devanshi Seth, BSc, PhD. Primary supervisor A/Prof PS Haber.
2002-2003 Rohan B Williams, BSc, PhD (UNSW). Primary supervisor Prof W. Britton.
2002-2006 Heather M Knott, BSc (Hons) PhD (Univ Sydney).
2005-2006 Joohong Park, BSc, M Sc, and PhD (Univ Sydney).
2006-2010 Denise MT Yu, B Med Sci (Hons) PhD (Univ Sydney).
2007-2008 Xin (Maggie) Wang, BSc (Peking), MSc (Univ Sydney) PhD (Univ Sydney).
2008-2009 Sunmi Song (BSc (Hons) PhD (Univ Sydney).
2008-2015 Fiona M. Keane BSc PhD (Dublin)
2013-2015 Yiqian Chen BSc MSc PhD (Univ Sydney). From Nov 2013
2015Hui Zhang B Pharm (China) M Appl Sci (Univ Sydney) PhD (Univ Sydney). From July 2015
RESEARCH COOPERATION:
21/12/15
Page 11 of 31
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Dr Thilo Kaehne & Professor Dr Siegfried Ansorge, Institute of Immunology, Otto-von-Guericke
University, Magdeburg, Germany. “Epitope mapping antibodies to CD26 using a peptide library”,
1995-96. “Physiological significance and mechanism of action of DP IV in T cell proliferation”.
1995-2003.
Drs Wolfgang Rettig and Andreas Schnapp, Boehringer Ingelheim Pharma KG, Biberach-an-der-Riss,
Germany [then Vienna, Austria]. “Comparison of Dipeptidyl peptidase IV with Fibroblast Activation
Protein: Expression and role in liver cirrhosis”. 1996-2002.
Professor Gary Halliday, Department of Dermatology, University of Sydney. “Comparison of DP IV
with Fibroblast Activation Protein: Expression and role in human skin cancer”. 1997-2000.
Dr W. Bret Church, Faculty of Pharmacy, University of Sydney. “Modelling structures in the DPP-IV
gene family”. 1999-2000, 2006-.
Professor Ronald Dickinson, Royal Brisbane Hospital. "Adduct formation by DP IV in zomepirac
treated rodents". 1999-2001.
Associate Professor Charles Collyer, Molecular and Microbial Biosciences, University of Sydney.
“Structure of Dipeptidyl Peptidases”. 2002-2005.
Dr George Marinos, St George Hospital. “Markers of fibrosis in hepatitis C virus infected human liver”.
1998-1999.
Professor Paul Haber, Drug Health Services, RPAH, "Pathogenesis of alcoholic liver disease". 20012007.
University of Sydney HCV Pathogenesis Consortium, including Prof. Geoff Farrell & Professor Jacob
George of Storr Liver Unit, Westmead Hospital and Prof. Geoff McCaughan. 2000-2008.
Dr Catherine Abbott, Flinders University of South Australia. “Biology and Biochemistry of DPP10,
DPP8 and DPP9”. 2001A/Pr Guy Cox, Electron Microscope Unit, Univ Sydney. “Novel method to image collagen fibers” 20022003, 2005-2007.
Professor Dr Ingrid De Meester, University of Antwerp, Belgium. “Enzymology of dipeptidyl peptidase
9”. 2005-2007.
Associate Professor Ossama El Kabbani, Victorian College of Pharmacy, Monash University,
Melbourne. “Structure of DPP-IV”. 2002-2007
Dr Rohan Williams, UNSW Dept Biotechnology, and Dr Josiah Poon, Univ Sydney Computer Science.
“Text recognition for understanding microarray data”. 2003-2006.
Dr Robert Brink, Centenary Institute. “Dipeptidyl peptidase gene deficient animals” 2002-2007.
Dr Alex Sharland, Transplant Surgery, University of Sydney. “NK cell surface proteins”. 2004-2009
Professor Stephen Twigg and A/Pr Sue McLennan, Endocrinology Centre, University of Sydney.
“Chronic liver disease in diabetes”. 2006Dr W Bret Church, Faculty of Pharmacy, University of Sydney. “Biochemistry of recombinant human
Kynurenine Aminotransferase-1”. 2006Professor Christopher M. Overall, University of British Columbia Centre for Blood Research,
Departments of Oral Biological and Medical Sciences and Biochemistry and Molecular Biology,
University of British Columbia, Vancouver, Canada. “DPP8 substrates” 2006-2008
Prof Eileen McLaughlin, Reproductive Science Group, ARC Centre of Excellence in Biotechnology
and Development, and School of Environmental and Life Sciences, University of Newcastle. DPPs
in testis.
Dr Kemal Topaloglu, Cukurova University, Faculty of Medicine, Department of Pediatric
Endocrinology and Metabolism, Balcalı, 01330 Adana, TURKEY. “Structure – function in DPPs”
2008 – 2010
Dr P. Bertolino and Dr C. Jolly, Centenary Institute. Lymphocytes in DPP knockout mice. 2008-2009.
Professor John Prins, Diamantina Institute, University of Queensland. DPP-IV in adipose tissue. 20082009.
Dr Soon Lee, RPAH Pathology Dept. DPP9 expression. 2008-2011.
Professor William Bachovchin, Tufts University, Boston. Dipeptidyl peptidase targeting for therapy and
measurement for diagnosis. 2010Professor Chris Semsarian, Centenary Institute. DPP polymorphisms. 2010.
Associate Professor Pu Xia, Centenary Institute. DPPs in cell signalling. 2009-2013. DPP4 in liver
cancer 2014-.
Dr Devanshi Seth, Centenary Institute and Drug Health Services, RPAH. DPPs in humans. 20112013.
Dr Oliver Schilling, Institute for Molecular Medicine and Cell Research, University of Freiburg.
Protease substrates. 2011-.
Dr Chuck Bailey, Gene Therapy, Centenary Institute. Protease expression in immortalised fibroblasts.
2012 - 2013.
21/12/15
Page 12 of 31
31. Dr Andrew Stephens, Ovarian Cancer Biomarker Research, Prince Henrys Institute for Medical
Research, Melbourne, 2012 32. Prof Andrew Lloyd, Dr Amany Zekry, UNSW and St George Hospital, University of New South Wales.
DPP-IV in HCV. 201233. Prof Nicholas Manolios, Dr Wendy Rhee [Lau], Dr Rani Sinnathurai. Westmead Hospital. DPPs in
arthritis. 2012-2014.
34. Dr Derek Spielman. Veterinary Science, University of Sydney. DPP9 knockout mouse pathology.
2013.
35. Professor Dr Pieter van der Veken and colleagues, University of Antwerp, Belgium. “Dipeptidyl
peptidase inhibition.” 2013-.
36. Dr Ruth Geiss-Friedlander, Georg-August-Universität Göttingen, Germany. “DPP9 biochemistry”.
201437. Dr Ben Roediger, Centenary Institute. Immune cells in Melanoma. 2014-.
OTHER PROFESSIONAL ACTIVITIES
MEMBERSHIP OF ONLINE ASSOCIATIONS
•
ORCHID . http://orcid.org/0000-0002-0528-2604
•
Linkedin
•
Research Gate
Service on Institutional Committees
✹ University of Sydney Genomics and Bioinformatics Consultative Committee 2001. Chair Prof Ron
Trent & Prof Tim Littlejohn
✹ University of Sydney Institutional Strengths Stream in Microbiology, Infectious Diseases, Immunology
and Host Defences Committee 2001. Chair Prof W. Britton
✹ Centenary Institute Equipment Committee 2001. Chair Dr Nicholas Pearce
✹ Centenary Institute Major Equipment Committee 2002-2003. Chair Prof Antony Basten
✹ Centenary Institute Safety Committee 2002-2003. Chair Mr Jeffrey Crosbie
✹ Centenary Institute Research Strategy Committee (occasional attendance by invitation) 2002-2004
Chair Prof Antony Basten.
✹ University of Sydney Discipline of Medicine Central School Postgraduate Student Review Committee
2003-present. Chair Prof Colin Sullivan.
✹ Centenary Institute Senior Academics Committee (occasional attendance by invitation) 2006 Chair
Prof David Burke.
✹ Centenary Institute Associate Faculty 2007- present. Chair Prof Mathew Vadas.
✹ Centenary Institute Postgraduate Studies Committee 2007-. Chair Prof C Semsarian.
✹ Centenary Institute Postgraduate Studies Committee Chair 2015-.
✹ Centenary Institute Equipment Committee. Chair A/Prof Mark Gorrell 2007- present.
✹ Charles Perkins Centre for Obesity Diabetes and Cardiovascular Diseases building user planning
committee 2010-2011.
✹ Centenary Institute Commercialisation Committee 2012-. Chair Dr N. Pearce.
✹ Centenary Institute Postgraduate Student Co-ordinator (HDR Sub-Dean) 2015-.
Service on Conference Committees
✹ Treasurer, International Congress on Differentiation and Cell Biology 2000. 1997-2000.
✹ Treasurer, Hunter Cellular Biology Meeting. [An annual conference] 2001-2005.
✹ Co-convenor of Liver Forum 11 Oct 2005. Sydney.
✹ Reviewer of Gastroenterological Society of Australia conference abstracts 2004-2015.
✹ International Proteolysis Society 2009: meeting organisation committee member.
✹ International Proteolysis Society 2015: Scientific Advisory Panel member. 2013, 2015.
✹ Co-convenor of conference on Diabetes Nov 2014. USA.
✹ Reviewer of APASL conference abstracts 2014.
✹ Judge of International Proteolysis Society poster awards 2013-2015.
✹ Judge of Gastroenterological Society of Australia conference awards 2014-2015.
✹ Judge of International Proteolysis Society orals awards 2015-.
✹ Combined Biosciences, Canberra. Judge of young investigator talks. 2014.
✹ Gastroenterological Society of Australia Research Committee member 2013-
21/12/15
Page 13 of 31
Conference Session Chair
✹ Hunter Cellular Biology Meeting 2003.
✹ Royal Prince Alfred Hospital Medical Officers Association Reunion Week June 2004.
✹ College of Health Sciences Conference, Leura, NSW, November 2004.
✹ The Australian Health and Medical Research Congress, Sydney, November 2004.
✹ International Congress on Dipeptidyl Amino Peptidases. Magdeburg, Germany 2005.
✹ College of Health Sciences Conference, Leura, NSW, November 2006.
✹ Australian Liver Association Apr 2013, May 2015.
✹ Conference on Diabetes Aug 2013. Chicago.
✹ Conference on Translational and Personalised Medicine. Aug 2013. Chicago.
✹ Conference on Diabetes Nov 2014. USA.
✹ COMBIO 2014. Combined Biosciences, Canberra.
✹ Australian Diabetes Society conference Adelaide. Poster session chair. 2015.
✹ International Proteolysis Society 2013, 2015.
✹ Gastroenterological Society of Australia conference 2015-.
Editorial Board Membership
✹ World Journal of Gastroenterology 2007-. Open access. Papers reviewed: 41. IF 3.3
✹ World Journal of Diabetes 2010-. Open access. IF 3.6
✹ World Journal of Hepatology 2012-. Open access.
✹ The Open Enzyme Inhibition Journal 2008-. Open access.
✹ Gastroenterology and Hepatology 2011-. Open access.
✹ WebMedCentral faculty member 2012-. Open access.
✹ Open Access Publishing 2013-.
✹ Scientific Reports 2014-. Open access run by Nature.com. Papers handled: 7, IF 5.56
Assess manuscripts for Journals
✹
Journals 1999-2005: Nature Structural Biology 2002. Lancet 2000. Protein Science x2. Clinical
Sciences 1999 [review]. Human Immunology. Journal of Gastroenterology and Hepatology.
Electrophoresis. GH & IGF (Growth hormone and insulin-like growth factor). BMC Genomics. EMBO
Reports. Biotechniques. Cytokine. Journal of Insect Cell Science. Cancer Investigation. Clinical
Chemistry 2005.
✹
Journals 2006: Current Medicinal Chemistry [review]. Liver International [x2]. EMBO Journal [x2].
Acta Pharmacologica Sinica. Cellular and Molecular Life Sciences [review]. World Journal of
Gastroenterology. Journal of Neurovirology.
✹
Journals 2007: World Journal of Gastroenterology [x10]. Journal of Neurovirology. FEBS Journal.
Journal of Investigative Dermatology. Medicine Today. Acta Pharmacologica Sinica. Liver
International. Expert Opinion on Medical Diagnostics [Informa Healthcare].
✹
Journals 2008: Trends in Immunology. Acta Biochimica et Biophysica Sinica. World Journal of
Gastroenterology [x3]. Liver International. Biochimica et Biophysica Acta - Proteins and Proteomics.
Expert Opinion on Pharmacotherapy [Informa Healthcare]. Journal of Cell Communication and
Signaling. FEBS Journal. EMBO Reports. Journal of Pathology.
✹
Journals 2009: Acta Pharmacologica Sinica. World Journal of Gastroenterology [x4]. FEBS Journal
[x2]. Liver International. Journal of Biomedicine and Biotechnology. Diabetes Obesity and Metabolism.
Molecular Cancer.
✹
Journals 2010: World Journal of Gastroenterology [x6]. Acta Pharmacologica Sinica [x2]. Liver
International. European Journal of Pharmacology. Inflammation & Allergy – Drug Targets. Journal of
Molecular Biology. Biological Chemistry. Advances in Clinical Chemistry. Expert Opinion on Drug
Discovery.
✹
Journals 2011: World Journal of Gastroenterology [x6]. Recent Patents on Endocrine, Metabolic &
Immune Drug Discovery. Expert Opinion on Drug Discovery. Cancer Epidemiology. Biomarkers and
Prevention. Journal of Medicinal Chemistry. Recent Patents on Endocrine, Metabolic & Immune Drug
Discovery. Journal of Endocrinology. Current Medicinal Chemistry. Regulatory Peptides.
Scandinavian Journal of Immunology. Expert Opinion on Therapeutic Patents. Disease Markers.
Journal of Physiology and Pharmacology. Liver International. Diabetes/Metabolism Research and
Reviews. Current Molecular Medicine.
✹
Journals 2012: European Journal of Histochemistry. World Journal of Gastroenterology x3. Acta
Pharmacologica Sinica x2. Protein & Peptide Letters. American Journal of Physiology:
Gastrointestinal and Liver Physiology. BioMedCentral Cell Biology. Reviews in Medicinal Chemistry.
Regulatory Peptides. Endocrinology.
21/12/15
Page 14 of 31
✹
✹
✹
Journals 2013: International Journal of Cardiology. Clinical and Experimental Immunology. World
Journal of Gastroenterology x 3. World Journal of Diabetes. World Journal of Hepatology. Journal of
Molecular Histology. BMC Cell Biology. Biofactors. Micron. Cellular and Molecular Life Sciences.
Scandinavian Journal of Immunology, Journal of the Royal Society Interface. Biomed Research.
Journals 2014: World Journal of Gastroenterology. Acta Pharmacologica Sinica. Contemporary
Oncology. BBA – Molecular Cell Research. BMC Cell Biology. Faculty of 1000. International Journal of
Molecular Sciences. Expert Review of Endocrinology & Metabolism. World Journal of Diabetes.
American Journal of Physiology-Endocrinology and Metabolism. American Journal of PhysiologyGastrointestinal and Liver Physiology. Molecular Pharmaceutics. British Journal of Pharmacology.
World Journal of Hepatology. Scientific Reports.
Journals 2015: World Journal of Gastroenterology x4. American Journal of PhysiologyGastrointestinal and Liver Physiology. British Journal of Pharmacology. Cancer Letters. Clinical and
Experimental Metastasis. European Journal of Pharmacology. American Journal of PhysiologyEndocrinology and Metabolism. Scientific Reports x5. BBA General Subjects. Scandinavian Journal of
Immunology. Frontiers in Immunology. J Neurochemistry. Apoptosis. World Journal of Hepatology.
World Journal of Diabetes. Peptides.
Assess grants for funding bodies since 1999
✹
✹
Grants: NHMRC of Australia 2002-2014, Diabetes Australia 2010-13. Wellcome Trust (UK; 20042006), USA Department of Agriculture (USDA; 1993-1998), Leo and Jenny Foundation, Auckland
Medical Research Foundation, International Federation of Science (Sweden; since 2005), Cure
Cancer Australia 2005, Raine Medical Research Foundation of Western Australia 2005. Netherlands
Organisation for Scientific Research. National Medical Research Council (Singapore) 2007-2014,
Austrian Science Fund (FWF). Czech Science Foundation. Institute Mérieux. Croation Science
Foundation. Medical Research Council of Portugal. Zurich Cancer League. National Science Centre of
Poland.
2014-2015 Grants: Grant Review Panel of NHMRC of Australia. GESA grants and awards.
Rebecca L Cooper Medical Research Foundation Scientific Advisory Committee. Diabetes Australia.
Service to industry
✹ Consultant in biotechnology to three firms during the years 1987 to 1989.
✹ Honorary consultant to Cryosite Ltd regarding ATCC cell lines 2003-2009.
✹ Advisor on dipeptidyl peptidase IV inhibitor selectivity to pharmaceutical research companies: Seven
companies since 2003, including Takeda, Forest, Sanofi-Aventis, Glenmark, Lupin, Torrent,
Boehringer Ingelheim.
✹ Consultant on dipeptidyl peptidases to Bristol-Meyers Squibb 2007-2009 and to Boehringer Ingelheim
2009.
Other Service
✹ Personal computing: Established Apple local area network (LAN) and internet access at
Neurovirology, Johns Hopkins Univ 1993. Manage Apple PCs in the Liver Lab 1996- 2006.
✹ Cosupervision of numerous PhD students and research assistants since 1982-1996, in addition to
those listed above.
✹ Treasurer, Australia & New Zealand Society for Cell and Developmental Biology 1994 -1996.
✹ Advisory Board member, International Federation of Science. 2007✹ International Advisory Panel for the 8th General Meeting of the IPS 2012-2013.
✹ Research Committee, Gastroenterological Society of Australia (GESA) 2013-2015.
MEMBERSHIP OF PROFESSIONAL SOCIETIES
•
American Society for Virology [life member 2005-] 1990 -.
•
American Association for the Advancement of Science 1999 -.
•
Australia & New Zealand Society for Cell and Developmental Biology (ANZSCDBI) 1989 - (Governing
Committee member 1994-1998, Treasurer 1994-1996).
•
Australian Society for Biochemistry and Molecular Biology (ASBMB) 2002 -.
•
Australian Society for Immunology 1980 -.
•
Gastroenterological Society of Australia 1996 -. Research Committee member 2013-16.
✹ International Proteolysis Society 2000 -. Treasurer and Governing Council member 2011-2015.
•
The Sydney Protein Group 1989 -.
•
NHMRC Research Translation Faculty. Aug 2012 -.
•
21/12/15
Page 15 of 31
•
•
•
•
•
New York Academy of Sciences 1994 - 2005.
Australian Society for Medical Research 1994 - 2001.
The Immunology Council, The Johns Hopkins University 1990 - 1994.
Australian Society for Veterinary Pathology 1986 - 1989.
European Association for the Study of Diabetes 2008 - 2013.
RESEARCH EXPERIENCE
I have trained in immunology, biochemistry, virology, liver disease pathogenesis, and serology. I was
primarily in veterinary research until re-training into medical research at Johns Hopkins University 1990-93.
I am now primarily interested in the pathogenesis of cirrhosis and the roles of dipeptidyl peptidase (DPP) 4,
DPP8, DPP9 and FAP (fibroblast activation protein).
From 1977 to 1981 during my Honours and PhD research on fascioliasis I became familiar with the
technologies of monoclonal antibody (MAb) production and characterization, serology and protein
biochemistry. In 1982 to 1983 I applied this experience to commercial research at Australian Monoclonal
Development Pty Ltd. in Sydney. The primary achievements of the team I led were in the production,
characterization and application to immunodiagnosis of highly specific MAbs to strains of Brucella abortus
and to bovine immunoglobulins.
In 1984 I made and characterized MAbs to sommatotropins. These MAbs were applied to academic
and commercial research on recombinant growth hormones.
The research on pig growth hormone was sponsored by the agricultural company Bunge Australia Pty Ltd.
In 1985 I moved my career into academic research. From 1985 to 1988 I oversaw the MAb laboratory
in what is now The Centre for Animal Biotechnology, headed by Dr Mal Brandon. The Centre has been at
the forefront of sheep immunology since 1984. In this position I worked on producing, characterizing and
using MAbs to sheep leukocyte cell surface differentiation antigens. We studied lymphocyte phenotypes in
the liver, abomasum, intestine, lungs, skin, mammary glands, lymph nodes and blood of normal and
diseased sheep and cattle. I was involved in studying infections of Taenia hydatigena, Haemonchus
contortus, Fasciola hepatica, Trichostrongylus colubriformis and Mycobacterium bovis. Our most significant
discovery was that the normal liver contains large numbers of CD8loCD5- lymphocytes.
In 1988 and 1989 I worked with Dr Geoff McCaughan, Director of Research in the A. W. Morrow
Gastroenterology and Liver Centre and Physician in Charge of Transplant Hepatology, Australian National
Liver Transplant Unit. My focus was on rat dipeptidyl peptidase IV (DP-IV; CD26). We discovered that the
liver antigen gp110 is DP-IV, is on B cells (in addition to T cells, bile canaliculi, endothelium, epithelium,
kidney tubules and acinar cells), is a homodimer, and that it is upregulated both on rat T cells following
activation and in rat serum during liver regeneration.
In 1989 I moved to the Johns Hopkins University School of Medicine to study the pathogenesis of
sheep lentivirus with the research group that discovered this virus. With Professor Opendra Narayan DVM
PhD and colleagues (1) I determined that Visna virus does not infect T cells, (2) we contrasted the
immunopathology of virus isolates causing low and high levels of inflammation in brain, and (3) we studied
cytokine production by cocultures of SIV-infected macrophages with T cells. This work contrasts the sheep
lentivirus, which does not involve immunodeficiency, with the primate lentiviruses SIV and HIV.
From 1991 to 1993 I worked with the eminent expert in viral pathogenesis, Professor Diane Griffin
MD PhD. I studied a rodent encephalitic alphavirus model, Sindbis virus, examining the role of the four
nonstructural virus proteins in pathogenesis. I found that recombinant Sindbis nonstructural proteins,
derived from vaccinia but not from E. coli, can confer protective immunity upon mice by an antibodyindependent, possibly T cell dependent, mechanism. We also compared the cytokine profiles of brains and
spinal chords from immune and nonimmune mice. Like hepatitis C virus, Sindbis is a small negative strand
RNA virus.
In 1994 I returned to the Gastroenterology and Liver Centre to examine CD26/DP IV in more detail. I
am using knowledge of the CD26 gene cloned and sequenced in the Liver Centre. We stably transfected
CHO cells and purified both wild-type and catalytically inert recombinant soluble human CD26. We
dissected out structure/function relationships of CD26. We identified two residues essential for binding to
the ligand adenosine deaminase and two residues essential for enzyme activity. In collaboration with Dr
Bret Church I modelled the 3D structure of CD26. We are comparing DP IV with other dipeptidyl peptidases
such as fibroblast activation protein (FAP) and the novel enzymes DP8 and DP9 that we have cloned. We
make and purify enzymes in this work. We have found that FAP is expressed on activated hepatic stellate
cells in proportion to the degree of liver injury. The collagen digesting activity of FAP and ligand binding are
probably involved in the stellate cell mediated pathogenesis of cirrhosis. We use gene knockout mice in
these studies. I have become more directly involved in studying the pathogenesis of chronic liver diseases
21/12/15
Page 16 of 31
since 1998. Using gene arrays, we have identified novel molecules of interest and are studying some in
detail.
Since 2005 I have focussed on functions of the DPP-IV enzyme family and their roles in chronic liver
injury and diabetes. This work involves many collaborations; those colleagues are listed above.
My diverse experience in biochemistry, cell biology, liver disease pathogenesis, HIV-like brain viruses,
parasites, immunity and diabetes is being applied to several projects. My research group is focussed upon
understanding and improving therapies in the fields of diabetes and chronic liver diseases.
PUBLICATIONS
Total number of citations: 4,845 to Nov 2015.
Measured by Google Scholar.
[Measured By ISI: 2,604 to 2012. 2,029 to 2010. 1,835 to 2009. 1,603 to 2008. 1457 to 2007. 1375 to
2006]
Papers with >100 citations: Eleven papers that are shaded .
Papers with >30 citations within 5 years: Ten papers since 2003.
The topics of the most cited papers are: DPP4, DPP8, chemokines, FAP in liver, liver collagen / Second
Harmonic Generation / liver DNA array.
2006; Oravecz 1997, Levy 1999, Abbott 2000.
2009: Oravecz 1997, Abbott 2000, Ajami 2008, and some reviews.
2010: Oravecz 1997, Abbott 2000, Cox 2003, and some reviews.
2011: Oravecz 1997, Abbott 2000, Cox 2003, and some reviews.
2012: Cox 2003, and some reviews.
2013: Oravecz 1997, Levy 1999, Cox 2003 and some reviews.
2014: Oravecz 1997, Cox 2003, Abbott 2000, Levy 1999, Shackel 2002 and some reviews.
First author publications: 24
Senior author publications: 49: 30 data papers and 21 reviews / book chapters
2015 Hirsch’s h-Index = 38.
i10 index = 82
2010-2015 Hirsch’s h-Index = 28.
[Hirsch: Thirty-eight papers have been cited 38 or more times by Dec 2015.]
[i10: The number of papers that have been cited 10 or more times.]
Graph of citations per year [from Google Scholar]
450 400 350 300 250 200 150 100 50 0 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 * Denotes the most significant publications.
21/12/15
Page 17 of 31
Impact factors of 2015 [Google Scholar Journal Citation Reports]. Dec 2015.
JOURNAL ARTICLE
1.
Puri NK, Gorrell MD & Brandon MR 1987 Sheep MHC class II molecules. I. Immunochemical
characterization. Immunology 62: 567-573. (26 citations, IF 3.795).
2.
Emery DL, Puri NK, Dufty JH, Gorrell MD & Brandon MR 1987 A functional and biochemical
analysis of bovine class II MHC antigens using monoclonal antibodies. Veterinary Immunology and
Immunopathology 16: 215-234. (17 citations, IF 1.769).
3.
Gorrell MD, Willis G, Brandon MR & Lascelles AK 1988 Lymphocyte phenotypes in the intestinal
mucosa of sheep infected with Trichostrongylus colubriformis. Clinical and Experimental
Immunology 72(2): 274-279. PMCID: PMC1541552 (26 citations, IF 3.037).
Annotation: This is the first report of lymphocyte phenotypes in response to disease in sheep
Meeusen E, Gorrell MD & Brandon MR 1988 The presence of a distinct CD8+ and CD5- leucocyte
subpopulation in the sheep liver. Immunology 64(4): 615-619. PMCID: PMC1384981 (21 citations,
IF 3.795).
Annotation: This is the first phenotyping of these atypical liver T cells.
4.
5.
Gorrell MD, Miller HRP & Brandon MR 1988 Lymphocyte phenotypes in the abomasal mucosa of
sheep infected with Haemonchus contortus. Parasite Immunology 10: 661-674. (25 citations, IF
2.220).
6.
Meeusen E, Gorrell MD, Rickard MD & Brandon MR 1989 Lymphocyte subpopulations of sheep in
protective immunity to Taenia hydatigena. Parasite Immunology 11: 169-182. (24 citations, IF
2.220).
7.
Burrells C, Nettleton PF, Reid HW, Miller HRP, Hopkins J, McConnell I, Gorrell MD Brandon M R
1988 Lymphocyte subpopulations in the blood of sheep persistently infected with border disease
virus. Clinical and Experimental Immunology 76(3): 446-451. PMCID: PMC1541889 (24 citations, IF
3.037)
8.
Meeusen E, Barcham GJ, Gorrell MD, Rickard MD & Brandon MR 1990 Cysticercosis: Cellular
immune responses during primary and secondary infection. Parasite Immunology 12: 403-418.
(37 citations, IF 2.220).
9.
*McCaughan GW, Wickson J, Creswick PF and Gorrell MD 1990 Identification of the bile canalicular
cell surface molecule gp110 as the ectopeptidase dipeptidyl peptidase IV: An analysis by tissue
distribution, purification and N-terminal amino acid sequence. Hepatology 11: 534-544.
10.
Gorrell MD, Wickson J and McCaughan GW 1991 Expression of the rat CD26 antigen (dipeptidyl
peptidase IV) on subpopulations of rat lymphocytes. Cellular Immunology 134: 205-215.
11.
Saravanamuthu V, Foster RA, Ladds PW and Gorrell MD 1991 T and B lymphocyte subsets in
spermatic granulomas in five rams. Veterinary Pathology 28: 482-491. (6 citations, IF 1.979).
12.
McEntee MF, Gorrell MD, Adams RJ, Narayan O and Pitha P 1992 Tumour necrosis factor and
interleukin 6 production during interaction between activated CD4+ lymphocytes and simian
immunodeficiency virus-infected macrophages. Journal of General Virology 73: 1107-1113.
13.
*Gorrell MD, Brandon MR, Sheffer D, Adams R and Narayan O 1992 Ovine lentivirus is
macrophagetropic and does not replicate productively in T cells. Journal of Virology 66(5): 26792688. (113 citations, IF 4.609).
Annotation: This was the final proof that the HIV related virus of sheep does not infect T cells in sheep
blood. Also, I proposed here, long before is was accepted, that this virus primarily infects dendritic cells in
blood.
21/12/15
Page 18 of 31
14.
Gorrell MD, Townsend WL and Ladds PW 1995 The distribution of lymphocyte subpopulations in
normal and acanthotic ovine skin. Veterinary Immunology and Immunopathology 44: 151-167.
Annotation: This is the first report of lymphocyte phenotypes in sheep skin.
15.
Townsend WL, Gorrell MD and Ladds PW 1995 Major histocompatibility complex antigens in
normal, acanthotic and neaoplastic ovine skin: An association between tumor invasiveness and low
level MHC class I expression. Veterinary Immunology and Immunopathology. 45: 237-252.
16.
Abbott CA, Gorrell MD, Kobayashi Y, Kawasaki T, Liddle C, Bishop GA & McCaughan GW 1995
Increased serum levels of DPP IV in rats undergoing liver regeneration. International Hepatology
Communications. 4: 165-174. (15 citations, IF 2.735). This journal name is now Hepatology
Research.
17.
Townsend WL, Gorrell MD & Mayer R 1997 Langerhans cells in the development of skin cancer: A
qualitative and quantitative comparison of cell markers in normal, acanthotic and neoplastic ovine
skin. Pathology 29: 42-50. (12 citations, IF 2.290).
18.
*Gorrell MD, Lemm JA, Rice CM & Griffin DE 1997 Immunization with nonstructural proteins
promotes functional recovery of alphavirus-infected neurons. Journal of Virology . 71:(5) 3415-3419.
Annotation: This was the first indication that an alphavirus non-structural protein is a functional antigen.
19.
*Oravecz T, Pall M, Roderiquez G, Gorrell MD, Ditto M, Nguyen NY, Boykins R, Unsworth E &
Norcross MA. 1997 Regulation of the receptor specificity and function of the chemokine RANTES
(regulated on activation normal T cell expressed and activated) by dipeptidyl peptidase IV (CD26)mediated cleavage. Journal of Experimental Medicine 186(11): 1865-1872. (350 citations, IF
13.244).
Annotation: This is the first report of chemokine DPP-IV substrates and the biological effects of DPP-IV on
chemokine action. Still strongly cited after 12 years.
20.
*Levy MT, McCaughan GW, Abbott CA, Cunningham AM, Park JE, Rettig WJ & Gorrell MD. 1999
Fibroblast activation protein: A cell surface dipeptidyl peptidase and gelatinase expressed by stellate
cells at the tissue surface dipeptidyl peptidase and gelatinase. Hepatology 29(6): 1768-1778. (190
citations, IF 12.054).
Annotation: This is the first report of the expression of FAP on hepatic stellate cells (HSC) and that FAP
has gelatinase activity in liver. FAP is the only constitutively active ECM protease on the HSC surface.
21.
*Abbott CA, McCaughan GW, Levy MT, Church WB & Gorrell MD. 1999 Binding to human
dipeptidyl peptidase IV by adenosine deaminase and antibodies that inhibit ligand binding involves
overlapping, discontinuous sites on a predicted β propeller domain. European Journal of
Biochemistry. 266:798-810. PMID 10583373. (80 citations, IF 4.068). Note: Eur J Biochem is now
FEBS Journal
Annotation: An important paper. We showed which antibodies block ADA binding to DPP-IV. This data was
used in 2013 to show that these same antibodies block binding of the MERS virus to DPP-IV. We predicted
the structure of the DPP-IV protein, mapping all known biochemical data onto it and defining the two
essential contact sites of the ADA binding site five years before the crystallisation of ADA with DPP-IV
showed us correct (Weihofen et al JBC 2004).
22.
*Abbott CA, McCaughan GW & Gorrell MD. 1999 Two highly conserved glutamic acid residues in
the predicted beta propeller domain of dipeptidyl peptidase IV are required for its enzyme activity.
FEBS Letters 458 (3): 278-284. PMID 10570924. (104 citations, IF 3.372).
Annotation: Here we showed the importance of the DPP-IV propeller domain and its residues
Glu203Glu204 four years before the crystal structure of DPP-IV showed that the propeller exists and these
residues dictate the dipeptide specificity of this enzyme (Rasmussen et al Nat Stru Biol 2003; Gorrell 2003
Nat Stru Biol 10:3-5).
23.
*Abbott CA, D Yu, E Woollatt, GR Sutherland, GW McCaughan & MD Gorrell. 2000 Cloning,
expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog,
21/12/15
Page 19 of 31
DPP8. European Journal of Biochemistry 267: 6140-6150. PMID 11012666. (216 citations, IF
4.068). Annotation: First report of discovering the novel peptidase DPP8. The number of citations
greatly increased since 2005, when its significance was recognised. Note: Eur J Biochem is now
FEBS Journal
24.
Wang M, Gorrell MD, McCaughan GW, Dickinson RG. 2001 Dipeptidyl peptidase IV is a target for
covalent adduct formation with the acyl glucuronide metabolite of the anti-inflammatory drug
zomepirac. Life Sciences. 68(7): 785-797. (29 citations, IF 2.702)
25.
*Shackel N, McGuinness PH, Abbott CA, Gorrell MD & McCaughan GW. 2001 Identification of novel
molecules and pathogenic pathways in primary biliary cirrhosis: cDNA array analysis of intrahepatic
differential gene expression. Gut. 49:565-576. (124 citations, IF 14.660).
Annotation: First description of the hepatic transcriptome in human chronic liver disease using DNA arrays.
This paper identified many novel gene pathways.
26.
*Shackel N, McGuinness PH, Abbott CA, Gorrell MD & McCaughan GW. 2002 Insights into the
pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differential gene
expression. American Journal of Pathology. 167: 641-654. (160 citations, IF 5.071).
Annotation: First description of the hepatic transcriptome and of wnt pathway gene expression in hepatitis
C disease. It confirmed the Th1 paradigm of hepatitis C. This paper identified pathogenic pathways
previously unrecognized in liver injury.
27.
Levy MT, GW McCaughan, G Marinos & MD Gorrell. 2002 Intrahepatic expression of the hepatic
stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C
virus infection. Liver International. 22(2):93-101. (86 citations, IF 4.850).
28.
Wang M, MD Gorrell, CA Abbott, R Jaggi, D Marguet & RG Dickinson 2002 Hepatic covalent adduct
formation with zomepirac in the CD26-deficient mouse. Journal of Gastroenterology and Hepatology
17(1): 66-71. (11 citations, IF 3.550).
Annotation: The second paper on the DPP-IV gko mouse and the final proof that DPP-IV is an important
part of adducts that caused this drug to be withdrawn from sale.
29.
Seth D, M D Gorrell, P H McGuinness, M A Leo, C S Lieber, G W McCaughan, P S Haber 2003
SMART amplification maintains representation of relative gene expression: Quantitative validation
by real time PCR and application to studies of alcoholic liver disease in primates. Journal of
Biochemical and Biophysical Methods 55(1):53-66. (75 citations, IF 1.81).
30.
Cox, G., E. Kable, A. Jones, I. Fraser, F. Manconi and M. D. Gorrell (2003). Three-dimensional
imaging of collagen using second harmonic generation. Journal of Structural Biology 141(1):53-62.
Cover illustration. (310 citations, IF 3.28).
Annotation: The first report of applying a new technology, second harmonic generation, to detecting
collagen fibres in tissues using two-photon imaging. It has gained wide applicability, including in liver
histopathology to quantify fibrosis.
31.
*Ajami, K., C. A. Abbott, M. Obradovic, V. Gysbers, T. Kähne, G. W. McCaughan and M. D. Gorrell
(2003). “Structural requirements for catalysis, expression and dimerisation in the CD26/DPP-IV gene
family.” Biochemistry USA 42(3):694-701. (62 citations, IF 3.019).
Annotation: Novel structure-function data on DPP-IV and DPP8 catalysis.
32.
Lorey S, Stockel-Maschek A, Faust J, Brandt W, Stiebitz B, Gorrell, M, Kähne T, Mrestani-Klaus C,
Wrenger S, Reinhold D, Ansorge S, Neubert K (2003) Different modes of dipeptidyl peptidase IV
(CD26) inhibition by oligopeptides derived from the N-terminus of HIV-1 Tat indicate at least two
inhibitor binding sites. Eur J Biochem, 270: 2147-56. (38 citations, IF 4.7). (Now FEBS Journal)
33.
*Shackel NA, McGuinness PH, Abbott CA, Gorrell MD & McCaughan GW. (2003) Novel Differential
Gene Expression in Human Cirrhosis Detected by Suppression Subtractive Hybridisation.
Hepatology: 38 (3): 577-588. (59 citations, IF 12.054).
Annotation: This first use of Suppression Subtractive Hybridisation identified novel gene expression in HCV
cirrhosis.
21/12/15
Page 20 of 31
34.
Seth D, Leo MA, McGuinness PH, Lieber CS, Brennan Y, Williams RBH, Wang XM, McCaughan
GW, Gorrell MD, Haber PS (2003) Gene expression profiling of alcoholic liver disease in the baboon
(Papio hamadryas) and human liver. American Journal of Pathology. 163:2303-2317. (62 citations,
IF 5.07).
Annotation: First paper on hepatic gene expression in ALD and first to compare human with baboon
disease.
35.
Ajami K., Abbott C.A., McCaughan G.W., Gorrell M.D. (2004). Dipeptidyl peptidase 9 has two forms,
a broad tissue distribution, cytoplasmic localization and DPP-IV-like peptidase activity. Biochimica et
Biophysica Acta: Gene Regulatory Mechanisms. 1679:18-28. (97 citations, IF 6.33). [before 2008
the journal name was BBA - Gene Structure and Expression]
Annotation: Characterisation of the novel cDNA of DPP9 that we patented.
36.
*X.M. Wang, D.M.T. Yu, G.W. McCaughan, and M.D. Gorrell, (2005) Fibroblast activation protein
increases apoptosis, cell adhesion and migration by the LX-2 human stellate cell line. Hepatology
42(4): 935-945. (97 citations, IF 12.054)
Annotation: Evidence for pro-fibrotic action of FAP and DPP-IV.
37.
Chen T., Ajami K., McCaughan G.W., Gai W.-P., Gorrell M.D., Abbott C.A. (2006). Molecular
Characterization of a novel Dipeptidyl Peptidase Like 2 short form (DPL2-s) that is highly expressed
in the brain and lacks dipeptidyl peptidase activity. Biochim Biophys Acta: Proteins 1764:33-43. (18
Annotation: Our clone of DPL2 [DP10], which others have evidence is asthma-linked
38.
Denise M.T. Yu, Xin Maggie Wang, Katerina Ajami, Geoffrey W. McCaughan and Mark D. Gorrell
2006 Extra-enzymatic functions of the dipeptidyl peptidase (DP) IV related proteins DP8 and DP9 in
cell adhesion, migration and apoptosis. FEBS Journal 273 (11): 2447-2461. (50 citations, IF 4.07).
39.
Seth D, Gorrell MD, Cordoba S, McCaughan GW, Haber PS 2006 Intrahepatic gene expression in
human alcoholic hepatitis. Journal of Hepatology 45 (2): 306-320. doi
org/10.1016/j.jhep.2006.04.013. Cover illustration. (64 citations, IF 11.34).
st
Annotation: First paper on intrahepatic gene expression in human alcoholic hepatitis. Also, 1 to compare
human alcoholic hepatitis to steatosis.
40.
Huang, XX, McCaughan GW, NA Shackel, Gorrell MD 2007 Upregulation of pro-proliferative genes
and the ligand/receptor pair placental growth factor and vascular endothelial growth factor receptor 1
in hepatitis C cirrhosis. Liver International 27:960-968. (26 citations, IF 4.850).
41.
Seth, D., P. J. Hogg, M. D. Gorrell, G. W. McCaughan & P. S. Haber 2008 Direct effects of alcohol
on hepatic fibrinolytic balance: implications for alcoholic liver disease. Journal of Hepatology 48(4):
th
614-627. Accepted 11 Dec 2007, went online 8 Jan 2008. (42 citations IF 11.34).
42.
Ajami, Katerina, Melissa R. Pitman, Claire H. Wilson, Joohong Park, R. Ian Menz, Amanda E. Starr,
Jennifer H. Cox, Catherine A. Abbott, Christopher M. Overall and Mark D. Gorrell 2008 Stromal cellderived factors 1 alpha and 1 beta, inflammatory protein-10 and interferon-inducible T cell chemoattractant are novel substrates of dipeptidyl peptidase 8. FEBS Letters 582(5): 819-825. doi:
10.1016/j.febslet.2008.02.005 (48 citations IF 3.37).
Annotation: The first evidence of chemokine substrates of DPP8, an enzyme closely related to diabetes
therapeutic target DPP-IV, which inactivates nine chemokines.
43.
Joohong Park, Heather M. Knott, Naveed A. Nadvi, Charles A. Collyer, Xin M. Wang, W. Bret
Church, Mark D. Gorrell 2008 Reversible inactivation of human dipeptidyl peptidases 8 and 9 by
peptidases 8 and 9 by oxidation. The Open Enzyme Inhibition Journal 1: 52-61.
bentham.org/open/toeij/openaccess2.htm. (19 citations, IF 0.5)
44.
Peter Tran, Dale Christiansen, Adam Winterhalter, Andrew Brooks, Mark Gorrell, Benjamin
Lilienfeld, Jorg Seebach, Mauro Sandrin, Alexandra Sharland. 2008 Porcine cells express more than
one functional ligand for the human lymphocyte activating receptor NKG2D. Xenotransplantation 15:
321-332. (10 citations, IF: 2.840)
21/12/15
Page 21 of 31
45.
Manos, J, Arthur, J, Rose, B, Tingpej, P, Fung, C, Curtis, M, S.Webb, J, Hu, H, Kjelleberg, S,
Gorrell, M, Bye, P, Harbour, C. (2008) Transcriptome analyses and biofilm-forming characteristics of
a clonal Pseudomonas aeruginosa from the cystic fibrosis lung. Journal of Medical Microbiology, 57:
1454-65. (38 citations, IF: 2.51)
46.
Manos, J, Arthur, J, Rose, B, Bell, S, Tingpej, P, Hu, H, S.Webb, J, Kjelleberg, S, Gorrell, M, Bye, P,
Harbour, C. 2009 Gene expression characteristics of a cystic fibrosis epidemic strain of
Pseudomonas aeruginosa during biofilm and planktonic growth. FEMS Microbiology Letters 292:
107-14. (36 citations, IF: 2.17)
47.
Denise MT Yu, Katerina Ajami, Margaret G. Gall. Joohong Park, C. Soon Lee, Kathryn A. Evans,
Eileen A. McLaughlin, Melissa R. Pitman, Catherine A Abbott, Geoffrey W. McCaughan, Mark D.
Gorrell 2009 The in vivo expression of dipeptidyl peptidases 8 and 9. Journal of Histochemistry and
Cytochemistry 57(11): 1025-1040. doi: 10.1369/jhc.2009.953760. (46 citations, IF: 1.96)
48.
Denise MT. Yu, Loubnah Slaitini, Vanessa Gysbers, Antoinetta G.M. Riekhoff, Thilo Kähne, Heather
M. Knott, Ingrid De Meester, Catherine A. Abbott, Geoffrey W. McCaughan, Mark D. Gorrell. 2011
Soluble CD26/ dipeptidyl peptidase IV enhances human lymphocyte proliferation in vitro
independent of dipeptidyl peptidase enzyme activity and Adenosine Deaminase binding.
Scandinavian Journal of Immunology 73(2): 102-111. Accepted 1 Nov 2010. DOI: 10.1111/j.13653083.2010.02488.x (22 citations, IF 1.95)
49.
Lisa Lo, Susan V. McLennan, Paul F. Williams, James Bonner, Sumaiya Chowdhury, Geoffrey W.
McCaughan, Mark D. Gorrell, Dennis K. Yue, and Stephen M. Twigg (2011) Diabetes is a progression factor
for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis. Journal of
Hepatology 55: 435-44. PMID: 21184785 (32 citations, IF 11.34).
50.
SM Song, Shackel NA, Ajami K, Wang XM, McCaughan GW, Gorrell MD. 2011 Discoidin Domain Receptor
1: Isoform expression and potential functions in cirrhotic human liver. American Journal of Pathology. 178(3):
1134-1144. PMID: 21622624 (10 citations, IF 5.07).
51.
FM Keane, Nadvi NA, Yao T-W & Gorrell MD (2011) Neuropeptide Y, B-type natriuretic peptide,
substance P and peptide YY are novel substrates of fibroblast activation protein-α. FEBS Journal
278(8):1316-32. PMID: 21314817 (39 citations, IF 4.07)
Annotation: The first identification of natural bioactive peptide substrates of FAP shows they differ from
DPP4 and probably will prove significant in neurobiology, metabolism and cardiology.
52.
Tsun-Wen Yao, Woo-Shin Kim, Denise MT. Yu, George Sharbeen, Geoffrey W. McCaughan, KangYell Choi, Pu Xia, Mark D. Gorrell. (2011) A novel role of Dipeptidyl Peptidase 9 in EGF signaling
and function. Molecular Cancer Research 9: 948-59. 10.1158/1541-7786.MCR-10-0272. PMID:
21622624. (22 citations, IF 4.860)
53.
Fady N Akladios, NA Nadvi, J Park, JR Hanrahan, V Kapoor, MD Gorrell, WB Church. 2012 Design
and synthesis of novel inhibitors of human kynurenine aminotransferase-I. Bioorganic & Medicinal
Chemistry Letters 22(3):1579-81 (6 citations, IF 2.420)
Annotation: KAT-1 [Kynurenine Aminotransferase-I] is a schizophrenia therapy target.
54.
Sumaiya Chowdhury, Yiqian Chen, Tsun-Wen Yao, Katerina Ajami, Xin M Wang, Yury Popov, Detlef
Schuppan, Patrick Bertolino, Geoffrey W McCaughan, Denise MT Yu, Mark D Gorrell. 2013.
Regulation of dipeptidyl peptidase 8 and 9 expression in activated lymphocytes and injured liver.
World Journal of Gastroenterology. 19:2883-93. doi: 10.3748/wjg.v19.i19.2883. PMID 23704821. (11
citations, IF 2.67)
Annotation: Novel data on DPP4, DPP8 and DPP9 upregulation with disease and with disease –
associated triggers.
55.
Harstad, Eric B, Rosenblum , Jonathon, Gorrell, Mark D, Achanzar William E, Minimo L, Wu J,
Marthaler L, Gullo R, Ordway ND, Kirby Mark S, Chadwick Karen D, Cosma GN, Moyer Carolyn F.
2013. DPP4, DPP8, and DPP9 expression in cynomolgus monkey and Sprague-Dawley rat tissues.
Regulatory Peptides 186:26-35. Doi 10.1016/j.regpep.2013.07.003 (5 citations, IF 1.875)
21/12/15
Page 22 of 31
56.
Margaret G Gall, Yiqian Chen, Ana Julia Vieira de Ribeiro, Hui Zhang, Charles G Bailey, Derek
Spielman, Denise MT Yu and Mark D Gorrell. 2013 Targeted inactivation of Dipeptidyl Peptidase 9
enzyme activity causes mouse neonate lethality. Published 6 Nov 2013. PLOS ONE 8 (11):
e0078378. (5 citations, IF: 3.702). doi 10.1371/journal.pone.0078378.
http://dx.plos.org/10.1371/journal.pone.0078378
Annotation: Proof that DPP9 deficiency is lethal for young mice until weaning. An implication is that DPP4selective inhibitors are safe.
57.
Brenna Osborne, Tsun-Wen Yao, Xin Maggie Wang, Yiqian Chen, L. Damla Kotan, Naveed A.
Nadvi, Mustafa Herdem, Geoffrey W. McCaughan, John Allen, Denise MT. Yu, A. Kemal Topaloglu,
Mark D. Gorrell 2014 A rare variant in human fibroblast activation protein associated with ER stress,
loss of function and loss of cell surface localization. BBA Proteins and Proteomics 1844:1248-1259.
10.1016/j.bbapap.2014.03.015. PMID 24717288. epub 6 April 2014. accepted Apr 2014. (5
citation, IF: 2.747)
Annotation: The only analysis of humans lacking FAP expression: The cell biology and biochemistry
shows no detrimental effects.
58.
FM Keane, T-W Yao, S Seelk, M Gall, S Chowdhury, S Poplawski, JH Lai, Y Li, W Wu, P Farrell, A
Vieira de Ribeiro, B Osborne, D Yu, D Seth, K Rahman, PS Haber, AK Topaloglu, C Wang, S
Thomson, A Hennessy, J Prins, SM Twigg, SV McLennan, GW McCaughan, WW Bachovchin, MD
Gorrell 2014 Quantitation of fibroblast activation protein-specific protease activity in mouse and
primate organs including cirrhotic liver. FEBS open bio 4: 43-54. (10 citations, IF 1.54) DOI
10.1016/j.fob.2013.12.001 Accepted 2 Dec 2013. Online 11 Dec 2013.
http://www.sciencedirect.com/science/article/pii/S2211546313000752 PMID 3871272.
Annotation: The first comprehensive analysis of the bodily distribution of FAP and of FAP expression in
diabetes and cirrhosis compared with DPP4.
59.
Alireza Nematollahi, W. Bret Church, Naveed A. Nadvi, Mark D. Gorrell, Guanchen Sun 2014
Homology modeling of human Kynurenine Aminotransferase III and observations on inhibitor binding
using molecular docking. Central Nervous System Agents in Medicinal Chemistry. 14:2-9. doi
10.2174/1871524914666140416095523 . http://www.ncbi.nlm.nih.gov/pubmed/24739074 PMID
24739074. (1 citation, IF: 2.52)
60.
Kathryn H Williams, Ana Júlia Vieira de Ribeiro, Emilia Prakoso, Anne-Sophie Veillard, Nicholas A
Shackel, Belinda Brooks, Yangmin Bu, Erika Cavanagh, Jim Raleigh, Susan V McLennan, Geoffrey
W McCaughan, Fiona M Keane, Amany Zekry, Mark D Gorrell, Stephen M Twigg. 2015 Circulating
Dipeptidyl Peptidase 4 Activity Correlates with Measures of Hepatocyte Apoptosis and Fibrosis in
NAFLD in Type 2 Diabetes Mellitus and Obesity: A Dual Cohort Cross-Sectional Analysis. Journal
of Diabetes 7(6):809-19 (Nov). Accepted 18 Oct 2014. (3 citations, IF: 2.38) online: 22 Dec 2014
DOI: 10.1111/1753-0407.12237. PMID 25350950.
Annotation: Shows that DPP4 in serum is an indicator of liver damage.
61.
Kathryn H Williams, Ana Júlia Vieira de Ribeiro, Emilia Prakoso, Anne-Sophie Veillard, Nicholas A
Shackel, Belinda Brooks, Yangmin Bu, Erika Cavanagh, Jim Raleigh, Susan V McLennan, Geoffrey
W McCaughan, William W Bachovchin, Fiona M Keane, Amany Zekry, Stephen M Twigg*, Mark D
Gorrell*. 2015 Lower Serum Fibroblast Activation Protein Shows Promise in the Exclusion of
Clinically Significant Liver Fibrosis Due to Non-alcoholic Fatty Liver Disease in Diabetes and
Obesity. Diabetes Research and Clinical Practice 108(3): 466-72. (June) PMID 25836944
Accepted 20 Feb 2015. epub 11 March 2015 org/10.1016/j.diabres.2015.02.024 (0 citations, IF:
3.074) *equal senior authors
Annotation: Shows that normal levels of circulating FAP persist with low levels of fibrosis.
62.
Hui Zhang, Yiqian Chen, Carol Wadham, Geoffrey W McCaughan, *Fiona M Keane, *Mark D Gorrell
2015 Dipeptidyl peptidase 9 subcellular localization and a role in cell adhesion involving focal
adhesion kinase and paxillin. Biochimica et Biophysica Acta (BBA) Molecular Cell Research
1853(2): 470-80. DOI: 10.1016/j.bbamcr.2014.11.029. PMID 25486458. (1 citation, IF 5.019)
*equal senior authors
Annotation: Discovery that knockdown or inhibition of DPP9 downregulates cell adhesion and migration;
potential role of DPP9 in cancer.
21/12/15
Page 23 of 31
63.
Hui Zhang, Sadiqa Maqsudi, Adam Rainczuk, Nadine Duffield, Josie Lawrence, Fiona M. Keane,
Daniela Justa-Schuch, Ruth Geiss-Friedlander, *Mark D. Gorrell, *Andrew N. Stephens. 2015
Identification of novel dipeptidyl peptidase 9 substrates by two-dimensional differential in-gel
electrophoresis. FEBS Journal 282(19): 3737 - 57 Accepted 7 July (0 citations, IF 4.068) *equal
senior authors. doi 10.1111/febs.13371. PMID 26175140.
Annotation: Discovery of many potential new targets of DPP9 consistent with a role of DPP9 in cancer.
64.
Pok Fai Wong, Margaret G. Gall, William W. Bachovchin, Geoffrey W. McCaughan, Fiona M. Keane,
Mark D. Gorrell 2016 Neuropeptide Y is a physiological substrate of fibroblast activation protein:
enzyme kinetics in blood plasma and expression of Y2R and Y5R in human liver cirrhosis and
hepatocellular carcinoma. Peptides 75:80-95. Published online 3 Dec, 2015. accepted 20 Nov 2015
doi 10.1016/j.peptides.2015.11.004 PMID 26621486 (IF 2.01)
Annotation: Discovery that FAP is able to inactivate NPY in vivo. This paper developed our methods of
discovering physiological substrates of FAP.
REVIEWS
65.
Alton G G et al. (11 authors including M.D. Gorrell) 1984 Report of WHO consultation on
research requirements for brucellosis with the participation of FAO. 1983, Algiers. WHO,
Geneva.
66.
Gorrell MD, Mackay CR, Maddox JF, Rickard MD & Brandon MR 1986 Immunity to
endoparasites of sheep. In: Third World Congress on Genetics Applied to Livestock
Development. Nebraska, USA. pp. 581-590.
67.
Zink MC, Gorrell MD & Narayan O 1992 The neuropathogenesis of visna virus infection in sheep.
In: Seminars in The Neurosciences. Volker ter Meulen (Ed). W. B. Saunders. Vol. 3 pp125-130.
68.
Narayan O, Zink MC, Gorrell MD, McEntee M, Sharma D & Adams RJ 1992 Lentivirus induced
arthritis in animals. J. Rheumatology 19: 25-32. (18 citations, IF 3.407).
69.
Narayan O, Zink MC, Gorrell MD, Crane S, Huso D, Jolly P, Saltarelli M, Adams RJ & Clements JE
1993 The lentiviruses of sheep and goats. In The Retroviridae Vol. 2 Jay A. Levy (Ed). Plenum, New
York pp229-256.
70.
Gorrell M.D., Abbott C.A., Levy M.T., Kähne T., Church W.B. & McCaughan G.W. 2000 Relating
structure to function in the beta-propeller domain of dipeptidyl peptidase IV Advances in
Experimental Medicine and Biology, 477: 89-95. (15 citations, IF 1.958)
71.
*G.W. McCaughan, M.D. Gorrell, G.A. Bishop, C.A. Abbott, N.A. Shackel, P.H. McGuinness, M.T.
Levy, A. Sharland, D.G. Bowen, D. Yu, L. Slaitini, W.B. Church, J. Napoli 2000 Molecular
pathogenesis of liver disease: An approach to hepatic inflammation, cirrhosis and liver transplant
tolerance. Immunological Reviews: Liver Defence and Disease. 174:172-191. (80 citations, IF
10.120).
72.
Abbott C.A., Yu D., McCaughan G.W. & Gorrell M.D. 2000 Post proline peptidases having DP IV
like enzyme activity Advances in Experimental Medicine and Biology 477: 103-109. (23 citations, IF
1.958)
73.
*Gorrell MD, Gysbers V & McCaughan GW. 2001 CD26: A multifunctional integral membrane and
secreted protein of activated lymphocytes. Scandinavian Journal of Immunology 54:249-264. (263
Annotation: A comprehensive and impartial review of DPIV (CD26) biochemistry and immunology. 17
citations in 2012; thus it is a long-lived review.
74.
*Shackel NA, Gorrell MD & McCaughan GW. 2002 Gene array analysis and the liver. Hepatology.
36:1313-1325. Cover illustration. (53 citations, IF 12.054).
Annotation: This was the first published review on the gene array approach to the study of liver
pathobiology following publication of our 2 key papers – Shackel et al 2001, 2002.
21/12/15
Page 24 of 31
75.
Chen T, Ajami K, McCaughan GW, Gorrell MD, Abbott CA 2003 The Dipeptidyl Peptidase IV gene
family. Dipeptidyl aminopeptidases in health and disease, M Hildebrandt, B. F. Klapp, T. Hoffman,
H.-U. Demuth. Eds, ISBN 0-306-47717-3. Kluwer, NY, pp.79-86. Advances in Experimental
Medicine and Biology 524: 79-86 (30 citations, IF 1.958)
76.
Haber, P. S., Warner, R. D. Seth, M. D. Gorrell and G. W. McCaughan (2003). “Pathogenesis and
management of alcoholic hepatitis.” Journal of Gastroenterology and Hepatology. 18: 1332-1344.
77.
*Gorrell MD (2003) First bite. Nature Structural and Molecular Biology 10(1): 3-5. News & Views. doi
10.1038/nsb0103-3. (12 citations, IF 13.309).
78.
*Gorrell MD 2005 Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders.
Clinical Science. 108:277-292. (223 citations, IF 5.598).
Annotation: A “Clinical Science Editor's Choice” Review article. A comprehensive review of DPP-IV biology.
79.
Gorrell, M. D., X. M. Wang, Joohong Park, Katerina Ajami, Denise Ming Tse Yu, Heather A. Knott,
Devanshi Seth and Geoffrey W. McCaughan. (2006). "Structure and function in dipeptidase
peptidase IV and related proteins." In Dipeptidyl aminopeptidases in health and disease II, Uwe
Lendeckel, Dirk Reinhold & Ute Bank Eds, Kluwer, NY, Chapter 5, pp 45-54. Advances in
Experimental Medicine and Biology 575: 45-54. (20 citations, IF 1.958).
80.
Shackel NA, Seth D, Haber PS, Gorrell MD, McCaughan GW 2006 The hepatic transcriptome in
human liver disease. Comparative Hepatology 5:6-16. doi:10.1186/1476-5926-5-6. (20 citations, IF
1.88).
81.
Wang XM, Yao T-W, Nadvi NA, Osborne B, McCaughan GW, Gorrell MD (2008). Fibroblast
activation protein and chronic liver disease. Frontiers in Bioscience: 13:3168-3180. DOI No:
10.2741/2918 http://www.bioscience.org/current/vol13.htm. (47 citations, IF 3.523)
82.
Manuela G. Neuman, Kevin Sha, Rustan Esguerra, Robert E. Winkler, Curtis L. Cooper, Nir
Hilzenrat, Jonathan Wise, Sam Zakhari, Devanshi Seth, Mark D. Gorrell, Paul S. Haber, Geoffrey
W. McCaughan, Maria A. Leo, Charles S. Lieber, Mihai Voiculescu, Eugenia Buzatu, Camelia
Ionescu, Jozsef Dudas, Bernhard Saile, Giuliano Ramadori. (2008) Inflammation and Repair in Viral
Hepatitis C. Digestive Diseases and Sciences. 53(6):1468-87. PMID: 17994278. (31 citations, IF:
2.613).
83.
Mark S. Kirby, Denise Ming Tse Yu, Steven O’Connor, Mark Gorrell 2010 Inhibitor selectivity in the
clinical application of dipeptidyl peptidase-4 inhibition. Clinical Science 118(1): 31-41. PMID
19780719 (122 citations, IF: 5.598) A “Clinical Science Editor's Choice” Review article.
84.
Yu DMT, Yao T-W, Chowdhury S, Nadvi NA, Osborne B, W. Bret Church, McCaughan GW, Gorrell MD
(2010). The Dipeptidyl Peptidase IV family in cancer and cell biology. FEBS Journal 277(1):1126-1144.
PMID 20074209 Invited Review (92 citations, IF 4.068)
85.
Kushner, P., and Gorrell, M.D. 2010. DPP-4 Inhibitors in Type 2 Diabetes: Importance of Selective Enzyme
Inhibition and Implications for Clinical Use. The Journal of Family Practice 59(2): http://www.jfponline.com.
(14 citations, IF 0.894)
86.
Schuppan, D, MD Gorrell, T Klein, M Marks, N Afdhal 2010 The challenge of developing novel
pharmacological therapies for non-alcoholic steatohepatitis. Liver International, 30, 795-808. PMID
20624207 (52 citations, IF 4.850)
Annotation: The first publication that a DPP-IV inhibitor can lessen liver damage from fatty liver.
87.
Jennifer H. Martin, Carolyn F. Deacon, Mark D. Gorrell, Johannes B. Prins 2011 Incretin-based
therapies – review of the physiology, pharmacology and emerging clinical experience. Internal
Medicine Journal 41: 299-307. PMID 21299778 (52 citations, IF 1.644)
88.
KH Williams, NA Shackel, MD Gorrell, SV McLennan, SM Twigg 2013 Diabetes and Non-Alcoholic Fatty
Liver Disease: A Pathogenic Duo. Endocrine Reviews 34(1): 84-129. PMID 23238855 (62 citations, IF
22.054)
21/12/15
Page 25 of 31
89.
Hui Zhang, Yiqian Chen, Fiona M. Keane, Mark D. Gorrell 2013 Advances in Understanding the
Expression and Function of Dipeptidyl Peptidase 8 and 9. Molecular Cancer Research 11(12): 14871496. Invited review. PMID 24038034 (10 citations, IF: 4.860)
90.
Elizabeth J. Hamson, Fiona M. Keane, Stefan Tholen, Oliver Schilling, Mark D. Gorrell 2014
Understanding Fibroblast Activation Protein (FAP): substrates, activities, expression and targeting
for cancer therapy. Proteomics Clinical Applications. 8(6): 454-463. DIO 10.1002/prca.201300095
Accepted 17 Oct 2013. Invited review. PMID 24470260 ( 13 citations, IF: 2.956)
91.
Gayan S. Jayawickrama, Richard R. Sadig, Guanchen Sun, Alireza Nematollahi, Naveed A. Nadvi,
Jane R. Hanrahan, Mark D. Gorrell, W. Bret Church 2015 Kynurenine aminotransferases and the
prospects of inhibitors for the treatment of schizophrenia. Current Medicinal Chemistry. 22(24):
2902-2918. accepted 4 June 2015 PMID 26051411 doi 10.2174/0929867322666150608094054
http://benthamscience.com/journal/abstracts.php?journalID=cmc&articleID=132068. (0 citations, IF:
4.115)
BOOK CHAPTERS
92.
Gorrell MD, Levy MT, Abbott CA & McCaughan, G.W. 1997 CD26: ADA binding, immunoblotting
and species cross reactivity examined using recombinant proteins. In: Leucocyte Typing VI (ed. T.
Kishimoto et al., Garland Publishing, Inc., New York. 484-485.
93.
Abbott C.A., Gorrell M.D. 2002 The family of CD26/DPIV and related ectopeptidases.
Ectopeptidases: CD13/Aminopeptidase N and CD26/Dipeptidylpeptidase IV in medicine and biology,
J Langner, S Ansorge Eds, ISBN 0-306-46788-7. Kluwer, NY, pages 171-194.
94.
*Gorrell MD & Yu DMT 2005 Diverse functions in a conserved structure: The dipeptidyl peptidase IV
gene family. In: Trends in Protein Research. John W. Robinson, editor. Nova Biomedical Books,
New York; ISBN 1-59454-153-1 USD80.10. Chapter 1. pp 1-78.
Annotation: The most comprehensive review of DPIV structure.
95.
*McCaughan GW, Shackel NA, Williams RBH, Seth D, Haber PS & Gorrell MD (2007) Genomics,
gene arrays and proteomics in the study of liver disease in The Textbook of Hepatology: From Basic
Science to Clinical Practice Editors Juan Rodés, Jean-Pierre Benhamou, Andres Blei, Jurg Reichen
and Mario Rizzetto. Jul 2007, 375 Pounds Sterling. ISBN 9781405127417 Blackwell, New York.
2360 pages. Chapter 3.6. Pages 398-420.
96.
*F. M. Keane, S. Chowdhury, T.-W. Yao, N. A. Nadvi, M. G. Gall, Y. Chen, B. Osborne, A. J. Vieira de
Ribeiro, W. B. Church, G. W. McCaughan, M. D. Gorrell, D. M. T. Yu [2012] Targeting Dipeptidyl Peptidase4 (DPP-4) and Fibroblast Activation Protein (FAP) for diabetes and cancer therapy. in B. Dunn (ed.),
Proteinases as Drug Targets. Royal Society of Chemistry, Cambridge, UK. RSC Drug Discovery Series No.
18. ISBN 978-1-84973-049-5. Chapter 5. Pages 119-145.
www.rsc.org/shop/books/2011/9781849730495.asp
97.
Abbott CA & MD Gorrell (2013) Dipeptidyl-peptidase 8. In Handbook of Proteolytic Enzymes 3rd Edition
(Rawlings ND & Salvesen G, eds). Chapter 746. pp 3379-3384. Elsevier, San Diego. ISBN 978-0-12382219-2. USD 795.00. http://www.elsevierdirect.com/ISBN/9780123822192/Handbook-of-ProteolyticEnzymes
98.
Gorrell MD & John E. Park (2013) Fibroblast activation protein alpha. In Handbook of Proteolytic Enzymes
3rd Edition (Rawlings ND & Salvesen G, eds). Chapter 750. pp 3395-3401. Elsevier, San Diego. ISBN 9780-12-382219-2. USD 795.00. http://www.elsevierdirect.com/ISBN/9780123822192/Handbook-of-ProteolyticEnzymes.
EDITORIAL/COMMENT/LETTER
99.
McCaughan GW, NA Shackel, MD Gorrell 2001 Differential gene expression between chronic
hepatitis B and C hepatic lesion (letter). Gastroenterology 121(5):1263-1264. (2 citations, IF
16.716).
21/12/15
Page 26 of 31
100. Gorrell MD, De Meester I. 2002 Meeting Report: International Conference on Dipeptidyl
aminopeptidases. Berlin, Germany, Sept, 2002. International Proteolysis Society Newsletter.
101. Gorrell MD, FJ Warner 2007 Fooling the liver: Malaria incognito. [Hepatology elsewhere
commentary] Hepatology 45(3):826. DOI: 10.1002/hep.21567. PMID 17326213 (1 citations, IF
12.054)
102.
Gorrell, Mark D 2007 Liver Fibrosis: The Hepatocyte Revisited. [Hepatology elsewhere
commentary] Hepatology 46(5):1659-1661. DOI: 10.1002/hep.22003 PMID 17969037. (10 citations,
IF 12.054)
103. Gorrell, Mark D 2008 Editorial: Impaired glucose tolerance and incretins in chronic liver disease.
Journal of Gastroenterology and Hepatology 23(2): 166-7. (1 citations, IF 3.550)
104. Sharland, Alexandra F. and Mark D Gorrell 2009 Co-operation of innate and adaptive immunity in
the pathogenesis of biliary atresia: there’s a killer on the run. [Hepatology elsewhere commentary]
Hepatology 50 (6):2037-2040. (3 citations IF 12.054)
105. Mark D Gorrell, Amany Zekry, Geoffrey W McCaughan, Andrew Lloyd 2011 The long and the short
of IP10 in HCV infection. [commentary] Hepatology. 54(5): 1875-78. (1 citations, IF 12.054)
106. Mark D Gorrell 2015 Commented upon F1000 article: Chakraborty S, Rendón-Ramírez A,
Ásgeirsson B, et al. Dipeptidyl peptidase-IV inhibitors vildagliptin and K-579 inhibit a phospholipase
C: a case of promiscuous scaffolds in proteins. [http://f1000r.es/51m] (10.12688/f1000research.2286.v3). Commentry DOI 10.5256/f1000research.6371.r7383
BOOK SECTION [most are peer-reviewed conference proceedings]
107. Gorrell MD, Milliken GL, Anderson BJ & Pucci A 1984 An enzyme immunoassay for bovine
brucellosis using a monoclonal antibody specific for field strains of Brucella abortus. Proceedings of
the Third International Symposium on Brucellosis. Algiers. Development of Biological Standards 56:
491-494. S. Karger, Basel. (5 citations,)
108. Abbott C.A., Gorrell M.D., Levy M.T. & McCaughan G.W. 1997 Molecular analyses of human and
rat dipeptidyl peptidase IV. In: Cellular Peptidases in Immune Function and Disease. (ed. S. Ansorge
& J. Langner). Plenum, New York. pp 66-70. Advances in Experimental Medicine and Biology 421:
161-169 (13 citations, IF 1.958)
109. Gorrell MD, Xin M. Wang, Miriam T. Levy, Eleanor Kable, George Marinos, Guy Cox, Geoffrey W.
McCaughan 2003 Intrahepatic expression of collagen and fibroblast activation protein (FAP) in
hepatitis C virus infection. Advances in Experimental Medicine and Biology 524: 235-243. (23
citations, IF 1.958)
110. Ajami K, Abbott CA, Gysbers V, Kähne Th., McCaughan GW, Gorrell MD 2003 Molecular chimeras
and mutational analysis in the prolyl oligopeptidase gene family. Advances in Experimental Medicine
and Biology 524:49-55. (IF 1.958)
111. Stockel-Maschek, Angela, Beate Stiebitz, Jurgen Faust, Ilona Born, Kähne Th., Gorrell MD, Klaus
Neubert 2003 Different Inhibition Mechanisms of Dipeptidyl Peptidase IV by Tryptophan Containing
Peptides and Amides. Advances in Experimental Medicine and Biology 524:69-72. (3 citation, IF
1.958)
112. Huang X.X., Gorrell M.D., Williams R., McCaughan G.W. 2004 A comparison of the liver
transcriptome in HCV versus HBV associated cirrhosis. Refereed Paper. Proceedings of the 11th
th
International Symposium of Viral Hepatitis and Liver Disease, 6 April 2003, Sydney. pp 304-305.
113. McCaughan G.W., Huang X.X., Zekry A., Beard M., Williams R., Gorrell M.D. 2004. The
intrahepatic response to HCV infection. Refereed Paper. Proceedings of the 11th International
th
Symposium of Viral Hepatitis and Liver Disease, 6 April 2003, Sydney. pp 100-106.
114. Park, J., K. Ajami, DMT Yu, MD Gorrell. (2006). "Dipeptidyl peptidase 8 has post-proline dipeptidyl
21/12/15
Page 27 of 31
aminopeptidase and prolyl endopeptidase activities." In Dipeptidyl aminopeptidases in health and
disease II, Uwe Lendeckel, Dirk Reinhold & Ute Bank Eds, Kluwer, NY, Chapter 10, pp 93-102.
Advances in Experimental Medicine and Biology 524:69-72. (3 citation, IF 1.958)
115. Wang, X. M., D. M. T. Yu, GW McCaughan, MD Gorrell (2006). "Extra-enzymatic roles of DPIV and
FAP in cell adhesion and migration on collagen and fibronectin." In Dipeptidyl aminopeptidases in
health and disease II, Uwe Lendecke, Dirk Reinhold & Ute Bank Eds, Kluwer, NY. Chapter 23 pp
213-222. Advances in Experimental Medicine and Biology 575: 213-222. (5 citations, IF 1.958)
116. Yu, D. M. T., X. M. Wang, GW McCaughan, MD Gorrell. (2006). "DP8 and DP9 have extraenzymatic roles in cell adhesion, migration and apoptosis." In Dipeptidyl aminopeptidases in health
and disease II, Uwe Lendeckel, Dirk Reinhold & Ute Bank Eds, Kluwer, NY, Chapter 7, pp 63-72.
Advances in Experimental Medicine and Biology 575:63-72. (4 citations, IF 1.958)
117. Banavar, M., Kable, E. P. W., Braet, F., Wang, X., Gorrell, M. D. & Cox, G. (2006). Detection of
Collagen by Second Harmonic Microscopy as a Diagnostic Tool for Liver Fibrosis. Proc SPIE. 6089,
60891B 1-12. (5 citations)
INVENTIONS
118. Meeusen E, Brandon MR, Gorrell MD, Walker J and Bowles VM. 1990 Vaccine composition. US
patent 7,470,908 (1990) and 08/070,632 (1993). Australian patent AU04903590. European patent
EP0381427. Assignee University of Melbourne. Patent expired.
119. Meeusen E, Brandon MR, Bowles VM, Walker J, Gorrell MD. 1997 Protective antigens against
disease pathogens. US patent 5,650,154. Assignee University of Melbourne.
Annotation: These two patents underpin a novel method of identifying candidate vaccine targets using
B cells from the site of infection.
120. Abbott CA, Gorrell MD Dipeptidyl Peptidases DPP8. PCT/AU00/01085, filed 11 Sept 2000, is
granted in USA: patents are 6881564 and 7148338. International Patent Application
WO00198468 filed from Australian Provisional Patent Application PQ2762. Assignee Sydney
South West Area Health Service. Applicant University of Sydney. National Phase April 2002.
Australian patent No. 767005 Granted 2004. Published US patent application 20040191826.
US Patent Application Number (PAN) 10/070464 filed 18 July 2002, published # WO01/19866
A1 on 22 March 2001 issued 2004 and patent # US 6,881,564 B1 granted 19 April 2005 for 20
th
years plus 163 days with priority date 10 September 1999. Derivative US Divisional PAN
10/825,632; patent # US 7,148,338 B2 granted 12 Dec 2006. European Patent No. EP1214344
B1 granted.
Feb 2010: The patent family is Granted in Australia, US, US (Continuation), Austria, United Kingdom,
Ireland, France, Denmark, Switzerland, Belgium, Spain, Italy, Netherlands, Germany, Luxemburg,
Finland, Portugal, Greece and Sweden. Under examination in Canada (Application No. 2384135) and
Japan (Application No. 2001-523643).
July 2011: Decision to abandon all but USA, Australia and Europe.
USA patent # US 6,881,564 B1 granted 19 April 2005 for 20 years plus 163 days with priority date
th
10 September 1999. 7,148,338 is US Divisional PAN 10/825,632; patent # US 7,148,338 B2
granted 12 Dec 2006. Austria – AT1214344. · Belgium – BE1214344 Switzerland - CH1214344
Germany - DE60029230 Denmark - DK1214344. Spain - ES1214344. France - FR 1214344.
United Kingdom - GB 1214344. Ireland - IE1214344. Italy - IT1214344. Netherlands - NL1214344.
Sweden - SE1214344
March 2015: Abandoned.
Annotation: This patent underpinned our DPP8 and DPP9 commercialization activities.
121. Abbott CA, Gorrell MD Dipeptidyl Peptidases DPP9. PCT/AU01/01388 International Patent
Application became granted USA patents 7276365, 7662944 and 7888094. Assignee
Sydney South West Area Health Service. Applicant University of Sydney. National Phase April
2003 in USA, Australia, Europe, Canada. Australian patent No. 2002214788 granted 11 Nov
th
2004 with priority date 27 October 2000. US patent application publication 2004/0053369 A1
th
published 18 march 2004. US Patent Application No. 10/415,122 filed 26 June 2003, issued
21/12/15
Page 28 of 31
10 Feb 2007, then 5 july 2007 became Granted Patent 7,276,365. European patent
Application No. 01983275.7 was allowed as patent number EP1337629. Danish Patent Number
DK1337629 (01983275.7) Granted 23 July 2007. Canadian patent allowed 2008. United States
patent application no. 11/904168, a Divisional of 10/415122 [Sydnovate ref: 2000-023-US-1],
titled Nucleic Acid Molecules Encoding Prolyl Dipeptidyl Peptidases [Dipeptidyl Peptidases
(human Dpp9)], was allowed Nov 2009 and Granted as 7662944 B2 on 16 February 2010 to
expire 5 May 2022. Divisional US Patent Application No. 12/702093 titled Dipeptidyl
Peptidases (Dpp9) on mouse DPP9 was filed 8 Feb 2010, allowed Oct 2010 and granted 15
February 2011 as US Patent Number 7888094. Sydnovate ref 10735.
March 2015: Abandoned.
Annotation: This patent underpinned our DPP8 and DPP9 commercialization activities.
122. Gorrell MD, S. Song, X.M. Wang 2009 Novel metabolic disease therapy. Australian Provisional
Patent Application [APPA] number 2009900275 filed 23 January 2009. Australian PCT
PCT/AU2010/000066 filed 22 January 2010. Applicants University of Sydney and Centenary
Institute. Sydnovate ref 2008-074-PRO-0. International patent application (PCT) titled “Novel
Metabolic Disease Therapy” published on 29 July 2010 as Publication No. WO 2010/083570.
WIPO: http://www.wipo.int/pctdb/images4/PCT-PAGES/2010/302010/10083570/10083570.pdf.
National phase 2012. Abandonded about March 2014.
Annotation: This patent did underpin our investigation of FAP as a therapeutic target for metabolic
syndrome associated conditions and diseases.
123. Gorrell MD, DMT Yu 2009 Peptidase Inhibitors. Australian Provisional Patent Application
2009902917 24 June 2009. Applicants University of Sydney and Centenary Institute. Sydnovate ref
2008-013-PRO-0. Abandoned.
PROTEIN STRUCTURES
4 WLH High resolution crystal structure of human kynurenine aminotransferase-I bound to PLP cofactor
1.28 Å resolution. 2014-12-3. NA Nadvi, NK Salam, J Park, FN Akladios, V Kapoor, CA Collyer, MD
Gorrell, WB Church.
4WLJ High resolution crystal structure of human kynurenine aminotransferase-I in complex with
aminooxyacetate 1.54 Å resolution. 2014-12-3. NA Nadvi, NK Salam, J Park, FN Akladios, V Kapoor, CA
Collyer, MD Gorrell, WB Church.
4WPO Crystal structure of human kynurenine aminotransferase-I with a C-terminal V5-hexahistidine tag
3.0 Å resolution. 2014-12-3. NA Nadvi, NK Salam, J Park, FN Akladios, V Kapoor, CA Collyer, MD Gorrell,
WB Church. http://www.rcsb.org/pdb/home/home.do
PRESENTATIONS SINCE 1998
INTERNATIONAL INVITED TALKS Since 1998
Roles of dipeptidyl peptidase IV and related enzymes in cirrhosis, skin cancer and immunity. Institute
of Internal Medicine, University of Magdeburg, Germany, Dec., 1998.
The structure and function of dipeptidyl peptidase IV and its role in T cell proliferation and chemotaxis.
Department of Clinical Biochemistry, University of Antwerp, Belgium, Dec., 1998.
Roles of fibroblast activation protein in cirrhosis and of dipeptidyl peptidase IV in inflammation.
Boehringer Ingelheim, Biberach-an-der-Riss, Germany, Dec, 1998.
Assessing intact human tissue. Liver Research Meeting. Lorne, Victoria, April, 1999.
Single amino acid point mutations within the predicted β-propeller domain of human dipeptidyl peptidase IV
(DPP IV/CD26) that ablate either adenosine deaminase binding, antibody binding or DPP IV enzyme
activity. Cellular Peptidases in Health and Disease II. Magdeburg, Germany. September, 1999.
21/12/15
Page 29 of 31
Intrahepatic expression of collagen and fibroblast activation protein (FAP) in hepatitis C virus
infection. International Conference on Dipeptidyl aminopeptidases. Berlin, Germany, Sept, 2002.
The DP-IV gene family: Structure and Function. Hunter Cellular Biology Meeting. NSW 12 April, 2003
nd
Structure-Function of DPIV. 2 International Congress on Dipeptidyl Amino Peptidases. Magdeburg,
Germany. 14 April, 2005. Invited plenary.
Peptidases as potential novel therapeutic targets for diabetes and fibrosis. ANU & University of Sydney
liver forum: research and its applications to prevent liver disease. Canberra. March 2007.
The Prolyl Oligopeptidase family. Institut Researches Servier, Paris, France. June 2006.
The biology of dipeptidyl peptidases explored in gene knockout mouse models. 3rd International
Symposium on Dipeptidyl peptidases and Related Proteins. Antwerp, Belgium 22-25 April, 2008. Invited
plenary.
Dipeptidyl peptidase IV inhibitor selectivity. Symposium on Incretin Therapies. 44th Annual Meeting of the
th
European Association for the Study of Diabetes. Rome, Italy 7 Sept, 2008. Invited symposium speaker.
Dipeptidyl peptidase IV inhibitor selectivity. Symposium: Clinical Crossroads in Type 2 Diabetes
Management: Optimizing Treatment Success. International Congress of Endocrinology. Rio de Janiero,
th
Brazil 7 Nov, 2008. Invited symposium speaker.
Role of DPP-4 and FAP in liver disease. Symposium: NAFLD, NASH and liver fibrosis. March 2009.
Marbach, Höri, Germany. Invited symposium speaker.
Gorrell M, Novel role of fibroblast activation protein in energy metabolism, 7th International Proteolysis
Society General Meeting, October 2011, San Diego, USA. Selected oral Presentation.
Hepatic steatosis and investigating incretin-based type 2 diabetes therapeutics for preventing NASH. Liver
Down Under . 28 Nov – 2 Dec 2011. Perth, Western Australia. Invited speaker.
Dipeptidyl peptidase IV and Fibroblast activation protein in liver diseases. Biochemistry Department,
Medical School, Tufts University, Boston. 24 April 2012. Invited speaker.
Fibroblast activation protein in chronic disease. Gordon Research Conference: Proteolytic Enzymes.
Lucca, Italy. 22-27 June 2012. Invited speaker.
M Gorrell. Fibroblast activation protein based diagnostics and therapeutics for liver diseases. Medical
School, Tufts University, Boston. 12 Aug 2013. Invited speaker.
M Gorrell. Human proteases as therapeutic targets and biomarkers in diabetes and its complications and in
hepatitis C. 1st International Conference on translational and personalised medicine. Chicago, USA. 05
Aug 2013. Invited speaker and session chair.
M Gorrell. Proteases as therapeutic targets and biomarkers in diabetes and its complications. OMICS
conference on diabetes. Chicago, USA. 17 Aug 2013. Invited speaker and session chair.
M Gorrell. The protease fibroblast activation protein as a biomarker and therapeutic target in cancer and
chronic liver injury. 2nd International Conference on Predictive, Preventive and Personalized Medicine &
Molecular Diagnostics. Las Vegas, USA. 3 Nov 2014. Invited speaker.
M Gorrell. Fibroblast activation protein is a potential biomarker and therapeutic target in diabetes and fatty
th
liver disease. 5 World Congress on Diabetes & Metabolism. Las Vegas, USA. 4 Nov 2014. Invited
speaker, session chair and conference convenor.
M Gorrell. Liver fibrosis. Arisaph Pharmaceuticals. Boston, USA. 13 Nov 2014. Invited speaker.
M Gorrell. DPP9 in cell growth adhesion and migration. Tufts University Medical School. Boston, USA. 14
Nov 2014. Invited speaker.
21/12/15
Page 30 of 31
M Gorrell. The sister proteases DPP4 and fibroblast activation protein as biomarkers and as therapeutic
targets in steatosis and fibrosis. AGW WGO 2015. Invited speaker and session chair.
M Gorrell. Fibroblast activation protein in diabetes.
session chair. Adelaide
ADS (diabetes society) 2015. Invited speaker and
M Gorrell. DPP9 in mice and cells: death, adhesion and migration. International Proteolysis Society .
Malaysia. 2015.
21/12/15
Page 31 of 31

Curriculum vitae - The University of Sydney

Transcription

Similar documents

Know Before You Go Sydney

Raider Readers PSJA North HS Library Raider Readers PSJA North

Liver Tests

PDF

transplante de figado em adultos

How to make a Madame Tussauds wax figure

the three c`s - Time for Kids

the liver beyond surgery in colorectal metastatic disease

VA-DMV Motor Carrier Operations